Protein tyrosine kinase 7 antibody and antibody-drug conjugate
By conjugating modified human IgG1 or IgG4 antibodies with topoisomerase I inhibitors to form stable antibody-drug conjugates, the stability and selectivity issues of existing ADCs in PTK-7 cancer treatment are solved, achieving highly efficient killing of PTK-7 overexpressing cancers and low-toxicity treatment.
Patent Information
- Application Number
- JP2026024715
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2024-04-26
- Filing Date
- 2026-02-18
- Publication Date
- 2026-05-18
- Estimated Expiration
- 2045-04-25
AI Technical Summary
Existing antibody-drug conjugates (ADCs) struggle to achieve efficient killing of PTK-7-overexpressing tumor cells while maintaining low toxicity and good stability against healthy cells, especially in cases of low PTK-7 expression and heterogeneous expression, lacking effective bystander therapeutic activity and immunogenicity.
Antibody-drug conjugates (ADCs) that specifically bind to human PTK-7 were developed. By modifying the Fc region and glycosylation site of modified human IgG1 or IgG4 antibodies, the binding ability to PTK-7 was enhanced. The ADCs were then conjugated with stable topoisomerase I inhibitors to form stable antibody-drug conjugates, ensuring effective drug release within tumor cells.
It achieves highly efficient killing of PTK-7 overexpressing cancers, reduces toxicity to healthy cells, improves bystander therapy efficacy for PTK-7 low-expressing tumors, maintains the chemical and physical stability of the drug, and enhances its pharmacokinetic stability in vivo.
Smart Images

Figure 0007861240000001 
Figure 0007861240000002 
Figure 0007861240000003
Abstract
Description
[Technical Field]
[0001] (Reference to the sequence list) This application is filed together with a sequence listing in ST.26XML format. The sequence listing is 202 Provided as a file titled "30976_WO" created on January 30, 2005. The size is 63 kilobytes. The sequence listing information in ST.26XML format is as follows: This is incorporated herein by reference.
[0002] (Field of Invention) This disclosure pertains to the field of medicine. More specifically, this disclosure pertains to protein tyrosine kinases. Ze7 (PTK-7) antibody, antibody-drug conjugate, and pharmaceutical composition thereof, and cancer Regarding their use in the treatment of [unspecified condition]. [Background technology]
[0003] PTK-7 belongs to the family of Wnt-related pseudokinases and is associated with triple-negative breast cancer. In addition, multiple tumor types such as non-small cell lung cancer, colorectal cancer, gastric cancer, esophageal cancer, and ovarian cancer. It is then overexpressed.
[0004] Antibody-drug conjugates (ADCs) for use in tumor therapy are introduced into tumor cells. A tumor-targeted anti-inflammatory drug conjugated into a payload designed to kill cells upon entry. Contains the body. Specific PTK-7 antibodies are included in the MMAE payload (International Publication No. 201516). (No. 8019) and camptothecin analog (Kong et al. Mol Cancer) It has been used to fabricate ADCs with the (Ther 22(10):1128) .
[0005] ADCs for use in oncology have sufficient specificity to tumor targets compared to healthy cells. Sex, acceptable toxicity, and maintenance of desired activity against bystander tumor cells, as well as An unstable payload that maintains good physical and chemical stability while enabling intracellular delivery. Because it requires balancing multiple molecular configurations, the design process is extremely difficult. It is a difficult compound. [Overview of the Initiative]
[0006] PTK-7 ADCs are still needed to treat cancer. In particular, PTK-7 has a sufficient therapeutic index based on good tolerability and / or better efficacy. ADCs not only effectively kill tumor cells, but are also well-tolerated by patients. It is necessary to support sufficiently high doses. In particular, effector null antibodies, PTK-7 ADCs with fully human antibodies and topoisomerase I payloads are still available. It is needed, in particular, for enhanced bystander treatment for PTK-7-low tumors. - Active PTK-7 ADCs are still needed, especially those with heterogeneous expression. PTK-7 A has enhanced bystander activity against tumors. DCs are still needed, especially those with low immunogenicity and stable in vivo pharmacokinetics. Furthermore, PTK-7 ADC with appropriate chemical and physical stability is still needed. Furthermore, it exhibits the following characteristics: better resistance in measurements in specific tumor models. Enhanced bystander activity against tumors, PTK-7-low tumors, and lower immunity. Lack of epidemiological efficacy, measurable antibody effector function, and lack of Fcγ receptor binding. PTK-7 having one or more of better physical and chemical stability and / or An ADC is still needed. The ADCs provided herein address one or more of these needs.
[0007] Provided herein are certain PTK-7 ADCs and compositions comprising PTK-7 ADCs. Also provided herein are methods of using compositions comprising PTK-7 ADC or PTK-7 ADC for cancer in a subject.
[0008] In one aspect, an antibody that binds to human PTK-7 is provided herein, the antibody comprising a heavy-chain variable region (VH) and a light-chain variable region (VL), wherein VH comprises heavy-chain complementarity-determining regions (HCDR) HCDR1, HCDR2, and HCDR3, and VL comprises light-chain complementarity-determining regions (LCDR) LCDR1, LCDR2, and LCDR3, wherein: a) HCDR1 comprises SEQ ID NO: 4, HCDR2 comprises SEQ ID NO: 5, HCDR3 comprises SEQ ID NO: 6, LCDR1 comprises SEQ ID NO: 7, LCDR2 comprises SEQ ID NO: 8, and LCDR3 comprises SEQ ID NO: 9; b) HCDR1 comprises SEQ ID NO: 14, HCDR2 comprises SEQ ID NO: 15, HCDR three comprises SEQ ID NO: 16, LCDR1 comprises SEQ ID NO: 17, LCDR2 comprises SEQ ID NO: 18, and LCDR3 comprises SEQ ID NO: 19; c) HCDR1 comprises SEQ ID NO: 24, HCDR2 comprises SEQ ID NO: 25, HCDR three comprises SEQ ID NO: 26, LCDR1 comprises SEQ ID NO: 27, LCDR2 comprises SEQ ID NO: 28, and LCDR3 comprises SEQ ID NO: 29; or d) HCDR1 comprises SEQ ID NO: 34, HCDR2 comprises SEQ ID NO: 35, HCD R3 contains SEQ ID NO: 36, LCDR1 contains SEQ ID NO: 37, LCDR2 contains SEQ ID NO: 18, and LCDR3 contains SEQ ID NO: 38.
[0009] In a further aspect, an antibody that binds to human PTK-7 is provided herein, and the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL). a) VH contains SEQ ID NO: 10 and VL contains SEQ ID NO: 11. b) VH contains SEQ ID NO: 20 and VL contains SEQ ID NO: 21. c) VH contains SEQ ID NO: 30 and VL contains SEQ ID NO: 31, or d) VH contains SEQ ID NO: 39 and VL contains SEQ ID NO: 40.
[0010] In another aspect, an antibody that binds to human PTK-7 is provided herein, and the antibody comprises a heavy chain (HC) and a light chain (LC). a) HC contains amino acids 2 to 441 of SEQ ID NO: 2 and LC contains SEQ ID NO: 3. b) HC contains amino acids 2 to 448 of SEQ ID NO: 12 and LC contains amino acids 2 to 215 of SEQ ID NO: 13. c) HC contains amino acids 2 to 447 of SEQ ID NO: 22 and LC contains amino acids 2 to 215 of SEQ ID NO: 23. d) HC contains amino acids 2 to 444 of SEQ ID NO: 32 and LC contains amino acids 2 to 215 of SEQ ID NO: 33.
[0011] In another aspect, provided herein is an antibody-drug conjugate (ADC) comprising a PTK-7 antibody disclosed herein conjugated directly or via a linker to a cytotoxic agent.
[0012] In a further aspect, an ADC is provided herein, and the cytotoxic agent is a can comprising Formula I. It is a putthecin analog.
[0013] [ka]
[0014] In another embodiment, an ADC of formula II is provided herein,
[0015] [ka] In the formula, Ab is a PTK-7 antibody disclosed herein, and n is approximately 1 to approximately 16.
[0016] In another embodiment, an ADC of formula III is provided herein,
[0017] [ka] In the formula, Ab is a PTK-7 antibody disclosed herein, and n is approximately 1 to approximately 16.
[0018] In another embodiment, the PTK-7 antibody disclosed herein and one or more pharmaceutically acceptable antibodies A pharmaceutical composition comprising a carrier, diluent, or excipient is provided herein. In this embodiment, PTK-7 ADC disclosed herein and one or more pharmaceutically acceptable A pharmaceutical composition comprising a carrier, diluent, or excipient is provided herein.
[0019] In another embodiment, an effective amount of PTK disclosed herein is administered to a patient in need of cancer treatment. A method for treating cancer, comprising administering ADCs, is provided herein. In a further embodiment, an effective amount of the PT disclosed herein is administered to a patient in need of cancer treatment. A method for treating cancer, comprising administering K-7 ADC, is provided herein. Cancers include ovarian cancer, lung cancer, breast cancer, stomach cancer, kidney cancer, prostate cancer, liver cancer, or It is colon cancer. [Modes for carrying out the invention]
[0020] PTK-7 As used herein, "human PTK-7" refers to colon cancer kinase-4 (CCK- 4) This refers to human protein tyrosine kinase 7, also known as human PTK-7. The amino acid sequence is NP_002812, which includes the signal peptide provided in SEQ ID NO: 1. It can be found there.
[0021] PTK-7 antibody (also known as anti-PTK-7 antibody) As used herein, the term “antibody” refers to an immunoglobulin that binds to an antigen. It refers to a molecule. Antibodies are any class (e.g., IgG, IgE, IgM, IgD, IgA) ), and any subclass (e.g., IgG1, IgG2, IgG3, IgG4) That's fine.
[0022] The exemplary antibodies of this disclosure are crosslinked via four polypeptide chains: interchain disulfide bonds. Immunoglobulin G is composed of two heavy chains (HC) and two light chains (LC). It is an IgG-type antibody. The amino-terminus of each of the four polypeptide chains is primarily responsible for antigen recognition. It contains a variable region of approximately 100 to 125 or more amino acids involved. (4 polypeptide chains) Each carboxyl terminus contains a constant region primarily involved in the effector function. Each heavy chain consists of a variable heavy chain region (VH) and a constant heavy chain region. Each light chain is a variable light chain region. It consists of a region (VL) and a light chain constant region. IgG isotypes are classified into subclasses (e.g., For example, it may be further divided into IgG1, IgG2, IgG3, and IgG4.
[0023] The VH and VL regions are referred to as the framework region (FR). Complementarity determining regions are areas where more conserved regions are scattered. It can be further subdivided into hypervariable regions called gions (CDRs). CDRs are the surface regions of proteins. These are exposed regions on the surface and are important areas of the antibody for antigen-binding specificity. Each VH and VL It consists of three CDRs and four FRs: FR1, CDR1, FR2, and CD The R2, FR3, CDR3, and FR4 are arranged in the order from the amino terminus to the carboxyl terminus. In this specification, the three CDRs of the heavy chain are referred to as "HCDR1, HCDR2, and HCDR3". The three CDRs of the light chain are referred to as "LCDR1, LCDR2, and LCDR3." DR contains most of the residues that form specific interactions with the antigen. C amino acid residues The assignment to DR is by Kabat (Kabat et al., "Sequences of Proteins of Immunological Interest,”N ational Institutes of Health,Bethesda,Md. (1991)), Chothia (Chothia et al., “Canonical al structures for the hypervariable regi ons of immunoglobulins”, Journal of Molec ular Biology,196,901-917(1987),Al-Lazika ni et al., “Standard conformations for th e canonical structures of immunoglobulin s”, Journal of Molecular Biology, 273, 927- 948 (1997)), North (North et al., “A New Clu stering of Antibody CDR Loop Conformatio ns”, Journal of Molecular Biology, 406, 228 -256(2011)), or IMGT (the International ImM The unoGeneTics database is available at www.imgt.org, L efranc et al., Nucleic Acids Res.1999;27: This is carried out in accordance with well-known schemes, including those described in 209-212. This may be done. The CDR of this disclosure shall be determined by North.
[0024] The specific antibodies described herein are derived from the IgG1 Fc region or human IgG1. Fc region, for example, a modified IgG1 Fc region having a modified Fc effector function Contains. IgG1 has antibody-dependent cell cytotoxicity (antibody-dependent cell cytotoxicity). ADCC) and complement-dependent cytotoxicity (CDC) It is known to induce [something]. Some of the antibodies in this disclosure have been introduced into the IgG1 Fc region. It has amino acid substitutions that alter the effector function. In part as disclosed herein If the mutation occurs, it occurs at positions 234 and 235 of the Fc region (according to EU index numbering). It is introduced into ( ). According to a portion disclosed herein, the mutation is introduced into position 2 of the Fc region. It will be introduced at locations 34, 235, and 265 (according to EU index numbering). In some embodiments, the PTK-7 antibody of this disclosure has alanine at residues 234 and 235, and Modified human IgG1 Fc region containing serine at position 265 (EU index numbering) (Also known as the hIgG1 effector null or hIgG1EN Fc region) Includes. In a further embodiment, some antibodies include glutamine, alanine, at position 297, or or glycine, alanine or glutamine at position 322, alanine or glutamine at position 329 It contains glycine and / or alanine or serine at position 331 (EU Index (by numbering), it has further mutations in the Fc region. In some embodiments, this These antibody mutations are alanine at position 234, glutamic acid at position 235, and position 237 These are alanine at position 330, serine at position 331, and serine at position 331 (EU index number 331). (by numbering). In a further embodiment, these amino acids introduced into the IgG1 Fc region The replacement reduced or eliminated the measurable antibody effector function.
[0025] In certain aspects of this disclosure, the PTK-7 antibody comprises one or more manipulated cysteine residues It contains a modified human IgG1 or human IgG4 constant domain. In a further embodiment, the antibody is , heavy chain steady domain 1 (CH1), heavy chain steady domain 2 (CH2), and / or heavy chain steady Contains cysteine manipulated at one or more sites within domain 3 (CH3).
[0026] Antibody expression in mammals typically leads to glycosylation. Antibody glycosylation is a typical process. In terms of structure, it is either an N-bond or an O-bond. N-bond glycosylation is an example of asparagine This refers to the attachment of the carbohydrate portion to the side chain of a residue. O-link glycosylation is a type of hydroxyaminoglycation. The binding of sugars to acids, such as N-acetylgalactosamine, galactose, or xylose It refers to a specific type of glycosylation. Typically, glycosylation involves highly conserved N-glycosylation sites (e.g., According to IMGT or EU Index numbering, it ranks 297th in IgG1. It occurs in the Fc region of the antibody. The glycosylation site is modified to alter the glycosylation. Obtain (for example, by blocking or reducing glycosylation, or by modifying and adding amino acid sequences) Alternatively, it generates various glycosylations.
[0027] Antibody expression in mammals from IgG subclasses involves the C-terminus from one or both heavy chains. This can result in amino acid cleavage, for example, in the case of an IgG1 antibody, one or Two C-terminal amino acids may be removed. In the case of IgG1 antibodies, the C-terminal lysine is present. In such cases, the heavy chain may be truncated or cleaved during expression. Similarly, the second-to-last glycine molecule can also be truncated or removed from the heavy chain.
[0028] Antibody expression in mammals can also result in modifications of the N-terminal amino acids, for example, heavy chains. Alternatively, if the most N-terminal amino acid of the light chain is glutamine or glutamic acid, pyrogluta It can be modified to lysine or glycan. For example, the C-terminal amino acid of the heavy chain or light chain may be lysine or glycan. If it is a synth, it may be removed.
[0029] The terms “nucleic acid” or “polynucleotide” are used interchangeably herein. , incorporating natural nucleotides, modified nucleotides, and / or nucleotide analogs Single-stranded and / or double-stranded nucleotide-containing molecules such as DNA, cDNA, and RNA molecules. This refers to a polymer of nucleotides containing DN. The polynucleotides of this disclosure also include, for example, DN A or RNA polymerase or a substrate incorporated therein by a synthetic reaction That's good too.
[0030] The polynucleotides of this disclosure are, for example, operable to expression regulatory sequences. After ligation, it can be expressed in host cells. Operablely ligated polynucleotides Expression regulatory sequences capable of expressing the expression vector are well known in the art. For example, expression vector The ter controls one or more signal peptides that promote the secretion of polypeptides from host cells. It may contain a sequence that signals. A signal peptide is, for example, an immunoglobulin signal peptide. It may be a polynucleotide or heterologous signal peptide. The target polynucleotide (e.g., antibody polynucleotide) Expression vectors containing polynucleotides encoding lipeptides are produced by well-known methods. It can then be transferred into host cells. Additionally, the expression vector is a desired polynucleotide sequence. To help detect host cells transformed with, for example, tetracycline, neomycosis It may include one or more selective markers, such as syn and dihydrofolate reductase.
[0031] Host cells are stable with one or more expression vectors expressing all or part of the antibodies of this disclosure. Includes cells that have been transfected, transformed, transduced, or infected, either permanently or transiently. According to several embodiments, host cells express the HC polypeptide of the antibody of this disclosure. Expression vectors that express actors and LC polypeptides, which can be transfused stably or transiently. It can be fected, transformed, transduced, or infected. In some embodiments, the host cell is The disclosed expression vector expresses the HC and LC polypeptides of the antibody, and is stable or It may be transiently transfected, transformed, transduced, or infected. The antibodies of this disclosure are used in this technology In accordance with well-known techniques in the field, lactation cells such as CHO, NS0, HEK293, or COS cells are used. It can be produced in animal cells.
[0032] The culture medium in which the antibodies of this disclosure are secreted is subjected to ion exchange and hydrophobic interaction chromatography. It can be purified by conventional techniques such as the mixing method. For example, the culture medium is conventional The method is used to apply to a Protein A or Protein G column and elute from it. This can be done, and a mixed method of ion exchange and hydrophobic interaction chromatography can also be used. This can be done. Soluble aggregates and polymers can be subjected to size exclusion, hydrophobic interactions, and ion interactions. Effectively removed by exchange or by common techniques including hydroxyapatite chromatography. The product can be removed by, for example, immediately freezing at -70°C, refrigerating, or freeze-drying. Drying may be performed. Various methods of protein purification may be used, and such methods may be performed using the technique It is known in the field of technology, for example, Deutscher, Methods in En Zymology 182:83-89 (1990), and Scopes, Protei n Purification:Principles and Practice,3 It is described in the rd Edition, Springer, NY (1994).
[0033] In one embodiment, an antibody that binds to human PTK-7 is provided herein, and the antibody is heavy-chain capable. It includes a variable region (VH) and a light chain variable region (VL), and VH is the heavy chain complementarity determining region (HCD). R)HCDR1, HCDR2, and HCDR3 are included, and VL is the light chain complementarity determining region (L CDR)Includes LCDR1, LCDR2, and LCDR3, where HCDR1 is sequence number 4 HCDR2 includes sequence number 5, HCDR3 includes sequence number 6, and LCDR1 LCDR2 contains sequence number 7, LCDR2 contains sequence number 8, and LCDR3 contains sequence number 9. In another embodiment, an antibody that binds to human PTK-7 is provided herein, and HCDR1 HCDR2 includes sequence number 14, HCDR2 includes sequence number 15, and HCDR3 includes sequence number 16. LCDR1 includes sequence number 17, LCDR2 includes sequence number 18, and LCDR3 This includes Sequence ID No. 19. In another embodiment, an antibody that binds to human PTK-7 is provided herein. Furthermore, HCDR1 includes sequence number 24, HCDR2 includes sequence number 25, and HCDR3 LCDR1 contains sequence number 26, LCDR1 contains sequence number 27, and LCDR2 contains sequence number 28. In addition, LCDR3 includes SEQ ID NO: 29. In another embodiment, an antibody that binds to human PTK-7. Provided herein, HCDR1 includes SEQ ID NO: 34, and HCDR2 includes SEQ ID NO: 35 Including, HCDR3 includes SEQ ID NO: 36, LCDR1 includes SEQ ID NO: 37, LCDR2 LCDR3 includes sequence number 18, and LCDR3 includes sequence number 38.
[0034] In one embodiment, an antibody that binds to human PTK-7 is provided herein, and the antibody is heavy-chain capable. The antibody includes a variable region (VH) and a light chain variable region (VL), and the antibody contains the VH and SEQ ID NO: 10. The present specification includes a VL containing SEQ ID NO: 11. In another embodiment, an antibody that binds to human PTK-7 is included in this specification. Provided in the document, the antibodies include VH containing SEQ ID NO: 20 and VL containing SEQ ID NO: 21. In one embodiment, an antibody that binds to human PTK-7 is provided herein, and the antibody is SEQ ID NO: 3 It includes VH containing 0 and VL containing SEQ ID NO: 31. In another embodiment, it is bound to human PTK-7. Antibodies are provided herein, and the antibodies include VH, which contains SEQ ID NO: 39, and SEQ ID NO: 40. Includes VL.
[0035] In a further embodiment, an antibody that binds to human PTK-7 is provided herein, wherein the antibody is heavy chain The antibody contains a variable region (VH) and a light chain variable region (VL), and the antibody is either human IgG1 or IgG4. It has an isotype. In a further embodiment, the antibody has a human IgG1 isotype. In a further embodiment, the antibody has residues 234 and 235 (according to EU index numbering) Contains alanine. In a further embodiment, the antibody is located at position 265 (according to EU index numbering). The compound further contains serine. In another embodiment, the antibody has a human IgG4 isotype.
[0036] In one embodiment, an antibody that binds to human PTK-7 is provided herein, and the antibody is, It includes a heavy chain (HC) and a light chain (LC), a) HC contains amino acids 2-441 of SEQ ID NO: 2, and LC consists of SEQ ID NO: 3. b) HC contains amino acids 2-448 of SEQ ID NO: 12, and LC contains amino acids of SEQ ID NO: 13. Contains 2-215 ano acids, c) HC contains amino acids 2-447 of SEQ ID NO: 22, and LC contains amino acids of SEQ ID NO: 23. Contains 2-215 ano acids, d) HC contains amino acids 2-444 of SEQ ID NO: 32, and LC contains amino acids of SEQ ID NO: 33. Contains 2-215 anoic acids.
[0037] In one embodiment, an antibody that binds to human PTK-7 is provided herein, and the antibody is heavy chain ( It contains HC and a light chain (LC), where HC contains amino acids 2-441 of SEQ ID NO: 2, and LC This includes Sequence ID No. 3. In one embodiment, an antibody that binds to human PTK-7 is provided herein. The antibody contains a heavy chain (HC) and a light chain (LC), and the HC is the amino acid of SEQ ID NO: 12. It contains amino acids 2-448, and LC contains amino acids 2-215 of SEQ ID NO: 13. In one embodiment, An antibody that binds to human PTK-7 is provided herein, and the antibody comprises a heavy chain (HC) and a light chain ( LC) contains amino acids 2-447 of SEQ ID NO: 2 It contains amino acids 2-215 of 3. In one embodiment, an antibody that binds to human PTK-7 is present in this specification. Provided in this document, the antibody contains a heavy chain (HC) and a light chain (LC), and the HC is the same as in SEQ ID NO: 32. It contains amino acids 2-444, and LC contains amino acids 2-215 of SEQ ID NO: 33.
[0038] In a further embodiment, an antibody that binds to human PTK-7 is provided herein, wherein HC is sequence It consists of number 2, and LC consists of sequence number 3. In another embodiment, it binds to human PTK-7. Antibodies are provided herein, where HC is from SEQ ID NO: 12 and LC is from SEQ ID NO: 13. In another embodiment, an antibody that binds to human PTK-7 is provided herein, and HC is, It consists of sequence number 22, and LC consists of sequence number 23. In another embodiment, human PTK-7 An antibody that binds to is provided herein, where HC is sequence number 32 and LC is sequence number It consists of No. 33.
[0039] In another embodiment, Sequence IDs 2 and 3, Sequence IDs 12 and 13, Sequence ID Polypeptide having amino acid sequences 22 and 23, 32 and 33 Different mammalian cells contain DNA molecules that include polynucleotide sequences encoding cytoplasm. The cells provided herein are capable of expressing the PTK-7 antibody disclosed herein. .
[0040] In another embodiment, a mammalian cell comprising a first DNA molecule and a second DNA molecule is described herein Provided to, the first DNA molecule coats a polypeptide having the following amino acid sequence. The second DNA molecule contains a polynucleotide sequence and has the following amino acid sequence The cells include a polynucleotide sequence encoding a polypeptide, as disclosed herein. The expression of PTK-7 antibodies is possible.
[0041] [Table 1]
[0042] In another embodiment, mammalian cells disclosed herein under conditions in which antibodies are expressed. The process involves culturing one of the PTK-7 antibodies and recovering the expressed antibody. A process for producing a body is provided herein.
[0043] In another embodiment, under conditions in which the antibody is expressed, Sequence IDs 2 and 3, sequence number Sequence ID 12 and Sequence ID 13, Sequence ID 22 and Sequence ID 23, Sequence ID 32 and Sequence ID 3 DNA containing a polynucleotide sequence encoding a polypeptide having a sequence of 3 amino acids By culturing mammalian cells containing the molecule and recovering the expressed antibody, The antibodies produced are provided herein.
[0044] In another embodiment, a mammalian cell comprising a first DNA molecule and a second DNA molecule, The first DNA molecule encodes a polypeptide having the following amino acid sequence. The second DNA molecule contains a sequence and encodes a polypeptide having the following amino acid sequence. Culturing cells containing polynucleotide sequences under conditions that allow antibody expression, Antibodies produced by recovering expressed antibodies are provided herein.
[0045] [Table 2]
[0046] As used herein, the term "cofetuzumab" is expressed using standard conditions. and purified human having the sequence disclosed in International Publication No. 2012112943 This refers to the anti-PTK-7 IgG1 antibody (hu6M024). The term "Aurista" refers to a severable valine-citrulline linker as a payload. This refers to an ADC containing tin-0101 and having a drug-to-antibody ratio (DAR) of 4.
[0047] payload The PTK-7 antibody of this disclosure can be used in various payloads (including its pharmaceutically acceptable salts). It can be conjugated to form an antibody-drug conjugate (ADC). The portion of the PTK-7 antibody disclosed in the document that is suitable for conjugation is cell damage. Harmful agents (e.g., chemotherapeutic agents), prodrug-converting enzymes, radioisotopes or compounds, toxins Examples include other payloads known in the art.
[0048] The exemplary ADCs described herein include camptothecin-based payloads (e.g., camptothecin-based payloads). Camptothecin analogs are used. Camptothecin analogs have been shown to have anticancer activity. Camptothecin and its analogues are topoisomerase I (TOPO1) inhibitors. The body prevents the re-annealing of partially severed DNA, and the accumulation of this DNA leads to cell death. It binds to the TOPO1 / DNA complex. Other camptothecin-like compounds known in the field. Body, for example, topotecan, irinotecan, SN-38, belotecan, exatecan, del Cuxtecan (Dxd), and its salts, such as exatecan mesylate, are used in the payload. It can be used as such.
[0049] In one embodiment, what is provided herein is an ADC, and the camptothecin analog is an E It is a satellite. In one embodiment, what is provided herein is an ADC and an exatecan. These are equations IV, V, or VI, respectively:
[0050] [ka] It contains one of the compounds.
[0051] Other payloads for ADCs known in the art include, for example, maytansinoids (e.g.) For example, DM1 and DM4), pyrrolobenzodiazepines (e.g., PBD dimers), Auri Statin peptides (e.g., MMAE and MMAF), duocalmycin, calicheama Icin, DNA accessory groove binders (e.g., enediin and lexitropsin), and taxa (For example, paclitaxel and docetaxel).
[0052] Self-immolative units Some ADCs exhibit self-immolation, or self-removal, which is a characteristic of A It can be designed within the overall structure of the DC. Self-destruction typically occurs when a trigger group is activated. This leads to spontaneous chemical and / or biological reactions, eliminating the group itself, i.e., the self-destructive unit. This includes causing the self-destructing unit to reach the peptide cleavage site within the ADC, which is a cell block. It provides good properties for ADCs, such as providing space to reduce steric hindrance of thease. It is possible.
[0053] In some aspects of this disclosure, the ADC described herein contains self-destructing units. If present, the self-destructing units on the ADC are converted into peptide units or molecules by cellular proteases. Exposure and induction occur after the ADC linker has been cleaved, such as by spore enzymes that cleave sugars. In a further embodiment, the self-destructing unit is para-aminobenzyloxycarbonyl (PABC) , ortho-aminobenzyl carbonate (OABC), or another self-destructing material known in the art. It is a sex unit.
[0054] In some aspects of this disclosure, the ADC described herein is a self-destructing unit of formula VII. Includes.
[0055] [ka]
[0056] In some aspects of this disclosure, the ADC described herein is a self-destructing single unit of formula VIII. Includes rank.
[0057] [ka]
[0058] In some aspects of this disclosure, the ADC described herein does not contain self-destructing units. i. In these embodiments, the camptothecin analogs described herein are peptide units or It is directly linked to the sugar-cleaving unit.
[0059] It is understood that the payloads described herein may exist as stereoisomers. The embodiments shown include all enantiomers, diastereomers, and mixtures thereof. .
[0060] Drug-to-antibody ratio (DAR) In this disclosure, when referring to a composition containing a population of ADCs, the average drug load is defined as the drug load per... The antibody ratio, or DAR, is the average number of drugs per antibody in the preparation, using conventional methods, e.g. For example, it can be characterized by mass spectrometry, HIC, ELISA, and HPLC. While a lower DAR can generate a more powerful ADC, higher DAR can also be unreliable. This leads to stabilization, aggregation, increased off-target toxicity, and enhanced drug clearance from systemic circulation. It can be done.
[0061] In some embodiments, DAR is 1 to about 16, about 2 to about 14, or about 2 to about 10. In one embodiment, the DAR is approximately 2 to approximately 5. In another embodiment, the DAR is 4 on average. In another embodiment, the DAR is approximately 6 to approximately 10. In yet another embodiment, the DAR is 8 on average. be.
[0062] In some embodiments, at least about 50%, 60%, and 7% of the ADC disclosed herein. 0%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% are 4 DAR It has. In some embodiments, at least about 50% of the ADC disclosed herein, 60% %, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% are 8 D It has AR. In some embodiments, the ADC disclosed herein is present in the composition. The ADC present in the composition is greater than approximately 1, 2, 3, 4, 5, 6, 7, or 8 on average. It has DAR.
[0063] Linker As disclosed herein, the payload is provided in a manner that can be understood by those skilled in the art. , conjugated with PTK-7 antibody to form PTK-7 ADC as described herein. It can be done. An example of such a conjugate is the payload described herein. This includes linking the code to the PTK-7 antibody described herein via a linker.
[0064] The linker used in ADCs allows time for the ADC to localize to the target cell. It is designed for stability in plasma. If the payload is released too quickly, all types The therapeutic index of ADCs decreases by damaging non-target tissues. Once internalized, the linker ensures that the payload can function as designed. It should provide a mechanism for releasing the payload.
[0065] A linker known to those skilled in the art includes, for example, a severable portion and an inseverable portion. Therefore, what is provided herein is a payload, for example, a camptothecin analog, The antibody is conjugated via a linker having a cleavable portion, or it is not cleavable. This is an ADC (antibody-conjugate cell) that is conjugated to an antibody via a linker having a possible portion.
[0066] Any suitable linker known in the art may be used in the preparation of the ADC of this disclosure. In certain embodiments, the linker can connect the antibody of this disclosure with a drug or cytotoxic agent. It contains reactive groups that can conjugate with both. For example, N-succinimidyl-4-(N- Maleimidomethyl)-cyclohexane-l-carboxylate (SMCC), N-succin Nimidyl-4-(iodoacetyl)-aminobenzoate (SIAB), bis-maleimi Polyethylene glycol (BMPEO), BM(PEO)2, BM(PEO)3, N- (β-maleimidopropyloxy)succinimide ester (BMPS), γ-maleimidopropyloxy N-succinimidyl dobutyrate (GMBS), N-hydro maleimidocaproate Xisuccinimide ester (EMCS), 5-maleimidovaleric acid NHS ester, N- Succinimidyl-4-(N-maleimidomethyl)-cyclohexane-l-carboxy-( 6-Amidocoproate), m-Maleimidobenzoyl-N-hydroxysuccinimide Ester (MBS), 4-(4-N-maleimidophenyl)-butyrate hydrazide or HCl Salt (MPBH), N-succinimidyl 3-(bromoacetamide)propionate (SBA P), N-succinimidyliodoacetate (SIA), k-maleimidoundecanoate N -Succinimidyl ester (KMUA), N-succinimidyl 4-(p-maleimide ester) (Nyl)-Butyrate (SMPB), Succinimidyl-6-(-Maleimidopropionamide) (D) Hexanoate (SMPH), succinimidyl-(4-vinylsulfonyl)benzoate (SVSB), dithiobis-maleimideethane (DTME), l,4-bis-maleimideethane Midobutane (BMB), l,4-bismaleidyl-2,3-dihydroxybutane (BM DB), bis-maleimidohexane (BMH), bis-maleimidoethane (BMOE), Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-l-carboxy Rate (sulfo-SMCC), sulfosuccinimidyl (4-iodoacetyl)aminobe Nzoate (sulfo-SIAB), m-maleimidebenzoyl-N-hydroxysulfate Xinimide ester (sulfo-MBS), N-(γ-maleimidobutyryloxy)sulf Foscusinimide esters (sulfo-GMBS or sGMBS), N-(e-maleimide) Caproyloxy) sulfosuccimid ester (sulfo-EMCS), N-(K-Malay Midounddecanoyloxy)sulfosuccinimide ester (sulfo-KMUS), and Sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate (sulfo-SMPB) succinimidyl 6-hydrazinonicotinamideacetone hydrazone (SANH), succinimidyl Sinimidyl 4-hydrazide terephthalate hydrochloride (SHTH), succinimidyl Hydrazinium nicotinate hydrochloride (SHNH), succinimidyl-p-formi Lubenzoate (SFB), and succinimidyl-p-formylphenoxyacetate ( SFPA), V-succinimidyl-3-(2-pyridyldithio)propionate (SPD P), V-succinimidyl-4-(2-pyridyldithio)pentanoate (SPP), N -Succinimidyl-4-(2-pyridyldithio)butanoate (SPDB), and V- Ccinimidyl-4-(2-pyridyldithio)2-sulfobutanoate (sulfo-SPDB ) are some examples, but are not limited to these.
[0067] In certain aspects of this disclosure, the ADC includes a detachable linker. Different mechanisms for releasing drugs or cytotoxic agents are known in the art. These mechanisms include (1) cellular enzymes (e.g., cathepsin B or β-glucuronidase) Therefore, by utilizing the protease cleavage site or other enzyme cleavage site in the linker that is cleaved, (2) Using lysosomes with a lower pH, hydrolysis of acid-unstable units in the linker (3) to cause or utilize higher intracellular levels of glutathione in the linker This involves reducing the disulfide bridges.
[0068] In some aspects of this disclosure, the ADC described herein is used for protease cleavage. It includes a linker containing peptide units that provide a site for the peptide. In some embodiments, the peptide The units are -Gly-Gly-Gly-, -Ala-Val-, -Val-Ala-, and -V al-Cit-, -Val-Lys-, -Lys-Val-, -Phe-Lys-, -L ys-Phe-, -Lys-Lys-, -Ala-Lys-, -Lys-Ala-, -P he-Cit-, -Cit-Phe,-Leu-Cit-, -Cit-Leu-, -Il e-Cit-, -Phe-Ala-, -Ala-Phe-, -Phe-Phe-Lys- , -Lys-Phe-Phe-, -Gly-Phe-Lys-, -Lys-Phe-Gl y-, -Leu-Ala-Leu-, -Ile-Ala-Leu-, -Leu-Ala- Ile-, -Val-Ala-Val-, -Ala-Leu-Ala-Leu-(SEQ ID NO. No. 49), -Leu-Ala-Leu-Ala- (Sequence No. 50), -Gly-Phe- Leu-Gly-(SEQ ID NO: 51), -Gly-Leu-Phe-Gly-(SEQ ID NO: 51) 2), -Val-Arg-, -Arg-Val-, -Arg-Arg-, -Ala-Al a-, -Ala-Met-, -Met-Ala-, -Thr-Thr-, -Thr-Me t-, -Met-Thr-, -Leu-Ala-, -Ala-Leu-, -Cit-Va l-, -Gln-Val-, -Val-Gln-, -Ser-Val-, -Val-Se r-, -Ser-Ala-, -Ser-Gly-, -Ala-Ser-, -Gly-Se r-, -Leu-Gln-, -Gln-Leu-, -Phe-Arg-, -Arg-Ph e-, -Tyr-Arg-, -Arg-Tyr-, -Phe-Gln-, -Gln-Ph e-, -Val-Thr-, -Thr-Val-, -Met-Tyr-, -Tyr-Me t-, -Ala-Ala-, -Ala-Ala-Ala-, -Ala-Ala-Ala- Ala-(SEQ ID NO: 53), -Gly-Ala-Gly-Gly-(SEQ ID NO: 54), - Gly-Gly-Ala-Gly-(SEQ ID NO: 55), -Gly-Val-Gly-Gl y-(sequence number 56), -Gly-Gly-Val-Gly-(sequence number 57), -Gl y-Phe-Gly-Gly-(SEQ ID NO: 58), or -Gly-Gly-Phe-Gl This is y-(sequence number 59). Citrulline is represented as Cit.
[0069] In aspects of this disclosure, the peptide unit contains all natural amino acids in L-amino acid form. In a further embodiment, the peptide unit is all D-amino acids or L-amino acids, or These may include combinations. Therefore, the peptide unit is, for example, D-Val -D-Ala, L-Val-L-Ala, D-Val-L-Ala, or L-Val-D -May include Ala
[0070] As used herein, the term “glycoclastic unit” refers to a unit like β-glucuronidase. Linker containing a sugar moiety that can be cleaved by enzymes such as lysosomal acid hydrolase. It refers to the internal part. In some aspects of this disclosure, the ADC provided herein is for cutting The linker includes a sugar-cleaving unit that provides a site for this purpose. In a further embodiment, the sugar-cleaving unit The position is a glucuronide or galactoside moiety, such as a β-glucuronide or β-galactoside moiety. In a further embodiment, the sugar-cleaving unit includes the β-glucuronide of formula IX.
[0071] [ka]
[0072] As used herein, the term “hydrophobic masking group” refers to the apparent hydrophobicity of a compound. This refers to a group that can reduce [something]. In some aspects of this disclosure, A as described herein DC, in particular the linkers described herein, are polysarcosine, polyethylene glycol, and It contains a hydrophobic masking entity of chito-oligosaccharide. In a further embodiment, polysarcosine, A hydrophobic masking group containing polyethylene glycol or chito-oligosaccharide is present on the linker. It is not connected in a linear chain, but rather has a branched three-dimensional arrangement. Examples of such branching arrangements can be found in formulas XXVI and XXI. The number of sarcosine moieties can vary widely. For example, in hydrophobic masking entities... The number of ethylene glycol or sarcosine moieties is 2-500, 5-100, or 5-2 It may be 5. In a further embodiment, the ADC provided herein has 2 to 50 sarcos n portion, 4-30 sarcosine portions, 6-24 sarcosine portions, or 10-12 It has a hydrophobic masking entity of polysarcosine containing the sarcosine moiety. Chito oligosaccharide The number of chitosan molecules inside can vary between 2 and 20, or between 2 and 8.
[0073] In aspects of this disclosure, the ADC includes a linker-payload connection unit that connects to the antibody. Includes a linker. In a further embodiment, the ADC provided herein is disclosed herein. The cysteine of the antibody is connected to the linker and / or payload described herein. It has a secondary unit. Some of the chemicals used in the art to attach to cysteine or comprises maleimide, succinimide, or bromoacetamide compounds, and A of the Disclosure It can be used in DC. In a further embodiment, CH2 and / or PEG (e.g., 2- Spacers such as PEG or 3-PEG chains are used as part of the linking unit. In a further aspect of the disclosure, maleimidocaproyl (mc) or maleimidomethylcyclohex Maleimide-type linking units such as sun-1-carboxylate are used.
[0074] In aspects of this disclosure, the antibody is conjugated via Michael addition by cysteinethiol. Maleimide-containing connecting units that form succinimide bonds and ADCs exist Either present or slowly converted to a ring-opening form by hydrolytic cleavage of succinimide in vivo. It can be converted.
[0075] In some aspects of this disclosure, an ADC having a connection unit of formula X is provided herein. And so,
[0076] [ka] In the formula, z is between 1 and 5.
[0077] In some aspects of this disclosure, an ADC having a connection unit of formula XI is provided herein. Served,
[0078] [ka] In the formula, z is between 1 and 5.
[0079] In some aspects of this disclosure, an ADC having a connection unit of formula XII is described herein. Provided,
[0080] [ka] In the formula, z is between 1 and 5.
[0081] In some aspects of this disclosure, an ADC having a connection unit of formula XIII is used herein. It is provided as follows:
[0082] [ka] In the formula, z is between 1 and 5.
[0083] In another embodiment, an ADC is provided herein, and the ADC is a product of formula II, IIa, or It is from IIb.
[0084] [ka] In the formula, Ab is a PTK-7 antibody disclosed herein, and n is approximately 1 to approximately 16.
[0085] In another embodiment, an ADC is provided herein, and the ADC is a compound of formulas III, IIIa, Or it is of type IIIb,
[0086] [ka]
[0087] [ka] In the formula, Ab is a PTK-7 antibody disclosed herein, and n is approximately 1 to approximately 16.
[0088] In a further embodiment, n is approximately 2 to approximately 12. In another embodiment, n is approximately 2 to approximately 8. In one embodiment, n is approximately 4 to approximately 8. In another embodiment, n is approximately 8 to approximately 12. In this case, n is approximately 2. In another embodiment, n is approximately 4. In yet another embodiment, n is approximately 6. In another embodiment, n is approximately 8. In another embodiment, n is approximately 10. In another embodiment, n It is approximately 12.
[0089] In one embodiment disclosed herein, Ab comprises amino acids 2-441 of SEQ ID NO: 2. The material comprises HC and LC including SEQ ID NO: 3, where n is approximately 8. In this case, Ab contains HC with amino acids 2-441 of SEQ ID NO: 2 and LC with amino acids 3. This includes and n is about 4. In further embodiments disclosed herein, Ab is Sequence ID No. 2 It includes HC consisting of and LC consisting of SEQ ID NO: 3.
[0090] In one embodiment disclosed herein, Ab comprises amino acids 2-448 of SEQ ID NO: 12. It contains HC and LC containing amino acids 2-215 of SEQ ID NO: 13, and n is approximately 8. In one embodiment disclosed in the specification, Ab is H containing amino acids 2-448 of SEQ ID NO: 12 This includes C and LC containing amino acids 2-215 of SEQ ID NO: 13, with n being approximately 4. In further embodiments disclosed in this book, Ab comprises HC consisting of Sequence ID No. 12 and Sequence ID No. 13 This includes LC.
[0091] In one embodiment disclosed herein, Ab comprises amino acids 2-447 of SEQ ID NO: 22 It contains HC and LC containing amino acids 2-215 of SEQ ID NO: 23, and n is approximately 8. In one embodiment disclosed in the specification, Ab is H containing amino acids 2-447 of SEQ ID NO: 22 This product contains C and LC containing amino acids 2-215 of sequence number 23, with n being approximately 4. In further embodiments disclosed in this book, Ab comprises HC consisting of Sequence ID No. 22 and Sequence ID No. 23 This includes LC.
[0092] In one embodiment disclosed herein, Ab comprises amino acids 2-444 of SEQ ID NO: 32. This contains HC and LC containing amino acids 2-215 of SEQ ID NO: 33, and n is approximately 8. In one embodiment disclosed in the specification, Ab is H containing amino acids 2-444 of SEQ ID NO: 32 This product contains C and LC containing amino acids 2-215 of SEQ ID NO: 33, with n being approximately 4. In further embodiments disclosed in this book, Ab comprises HC consisting of Sequence ID No. 32 and Sequence ID No. 33 This includes LC.
[0093] The linkers and linker-payloads described herein may exist as stereoisomers. It is understood that the embodiments of this disclosure include all enantiomers, diastereomers, and This includes a mixture of these.
[0094] Conjugate to anti-PTK-7 antibody The antibodies disclosed herein, the payload and linker-payload disclosed herein Methods for conjugating to a code are known in the art. Several methods are available. Then, the antibody is conjugated to the linker in the first reaction, and then the antibody and the linker The injector is conjugated to the payload in the second reaction. In several ways... The antibody is then conjugated to the payload or payload / linker in a single reaction. It will be done.
[0095] In some aspects of this disclosure, the PTK-7 antibodies described herein are PTK-7 anti- The following is described herein via the thiol groups of one or more cysteine residues located on the body It is covalently bonded to a camptothecin analog. In a further embodiment, it is used as a conjugate. Each of the cysteine residues is an interchain disulfide cysteine residue. This technology controls the reduction of cysteine, enabling its conjugation to the involved cysteine. It is publicly known in the field. In other embodiments, it is used separately from the conduit used for interchain disulfides. The cysteine residue used for the glycation is incorporated into the antibody through manipulation.
[0096] In some embodiments of the ADC disclosed herein, Ab is one or more cysteine residues. The linker-payload is conjugated via the thiol group of the group. In some embodiments, Ab is a cysteine residue in one or more HCs of Ab disclosed herein. It is conjugated via an all group. In some embodiments, Ab is conjugated via one or more cis groups. The cysteine residue is conjugated via the thiol group of the thene residue, and the cysteine is at C219 of the heavy chain. Selected from C225, C228, and the light chain C215, or a combination thereof. .
[0097] In other aspects of this disclosure, the PTK-7 antibody described herein is applied to the PTK-7 antibody. via the amino groups of one or more lysine residues located therein, the camptotheci described herein It is covalently bonded to an analog. In other aspects of this disclosure, PTK-7 described herein The antibody, via the amino groups of one or more glutamine residues located on the PTK-7 antibody, It is covalently bonded to the camptothecin analog described in the specification.
[0098] In one embodiment, what is provided herein is an ADC, a cytotoxic agent, a cytotoxic agent - The connection of a destructive spacer, or a cytotoxic agent-self-destructive spacer-linker to an antibody, is performed by the antibody It is generated via one or more thiol groups on cysteine. In a further embodiment, one or more cysteine Each of the steins is a native cysteine found in the hinge region of the antibody.
[0099] In one embodiment, an ADC is provided herein and is used with the PTK7 antibody described herein. The linker-payload used for the conjugate is of formula XIV or XV. .
[0100] [ka]
[0101] This disclosure provides a method for generating an ADC, and the method is (a) The PTK-7 antibody disclosed herein is reduced using a reducing agent, and the reduced P The process of producing TK-7 antibody, (b) Contact the reduced PTK-7 antibody with the compound of the present disclosure to produce a conjugate. A process in which the compound is formed, wherein the compound is a linker disclosed herein, such as formula XIV or XV. - A step including a payload, and. A further aspect is that the reducing agent is DTT or TCEP is.
[0102] The conjugate of the present disclosure or a salt thereof can be easily prepared by various procedures known to those skilled in the art and some of them are illustrated in the following preparations and examples. Those skilled in the art can combine the specific synthetic steps for each of the described routes in different ways to prepare the conjugate of the present disclosure or a salt thereof, or can combine them with different schemes recognize that they can be combined with other steps. The product of each step can be recovered by conventional methods well known in the art, including extraction, evaporation, precipitation crystallization, chromatography, filtration, grinding, and crystallization. All substituents are as defined above unless otherwise indicated. Reagents and starting materials are readily available to those skilled in the art. The following preparations, examples, and assays further illustrate the present disclosure but should in no way be construed as limiting the scope of the present disclosure should not be construed as limiting the scope of the present disclosure. are as already defined. Reagents and starting materials are readily available to those skilled in the art. The following preparations, examples, and assays further illustrate the present disclosure but should in no way be construed as limiting the scope of the present disclosure should not be construed as limiting the scope of the present disclosure.
[0103] therapeutic use In another aspect, there is provided herein a method of treating cancer comprising administering to a patient in need of treatment for cancer an effective amount of the PTK -7 ADC or pharmaceutical composition described herein. In a further aspect, there is provided herein a method of treating cancer comprising administering to a patient in need of treatment for cancer an effective amount of the ADC or pharmaceutical composition described herein wherein the cancer is ovarian cancer, endometrial cancer, lung cancer, head and neck cancer, thyroid cancer, breast cancer, gastric cancer cancer, kidney cancer, prostate cancer, liver cancer, pancreatic cancer, or colorectal cancer. is provided herein, and the cancer is ovarian cancer, endometrial cancer, lung cancer, head and neck cancer, thyroid cancer, breast cancer, gastric cancer cancer, kidney cancer, prostate cancer, liver cancer, pancreatic cancer, or colorectal cancer.
[0104] In a further aspect, a method of treating cancer is provided, wherein the cancer is ovarian cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is endometrial cancer. In a further aspect a method of treating cancer is provided, wherein the cancer is lung cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is head and neck cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is thyroid cancer. In a further aspect, a method of treating cancer is provided wherein the cancer is breast cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is gastric cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is kidney cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is prostate cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is liver cancer. In a further aspect a method of treating cancer is provided, wherein the cancer is pancreatic cancer. In a further aspect, a method of treating cancer is provided, wherein the cancer is colorectal cancer.
[0105] In a further aspect, a patient being treated with an ADC or pharmaceutical composition described herein is previously treated with a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, with or without platinum-containing chemotherapy, in a neoadjuvant / adjuvant, locally advanced or metastatic setting.
[0106] In a further aspect, a method is provided that includes administering an effective amount of an ADC or pharmaceutical composition described herein in combination with, separately from, or sequentially with one or more In a further embodiment, an effective amount of the ADC or pharmaceutical composition described herein is used in PD -1 inhibitors or PD-L1 inhibitors are administered simultaneously, separately, or in combination in sequence. A method is provided that includes the following.
[0107] In another embodiment, PTK-7 ADC or as described herein for use in therapy Pharmaceutical compositions are provided herein. In a further embodiment, for use in the treatment of cancer The ADC or pharmaceutical composition described herein is provided. In a further embodiment, cancer is Ovarian cancer, endometrial cancer, lung cancer, head and neck cancer, thyroid cancer, breast cancer, stomach cancer, kidney cancer It is prostate cancer, liver cancer, pancreatic cancer, or colorectal cancer.
[0108] In a further embodiment, the ADC described herein for use in the treatment of ovarian cancer Or pharmaceutical compositions are provided herein. In a further embodiment, in the treatment of endometrial cancer ADCs or pharmaceutical compositions described herein for use are provided herein. In one embodiment, the ADC or medical described herein for use in the treatment of lung cancer A pharmaceutical composition is provided herein. In a further embodiment, for use in the treatment of head and neck cancer Therefore, ADCs or pharmaceutical compositions described herein are provided herein. Further embodiments Therefore, for use in the treatment of thyroid cancer, the ADC or pharmaceutical combination described herein Products are provided herein. In a further embodiment, for use in the treatment of breast cancer, ADCs or pharmaceutical compositions described in the specification are provided herein. In a further embodiment, the stomach For use in the treatment of cancer, the ADCs or pharmaceutical compositions described herein are... is provided in the book. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of kidney cancer is provided in the present specification. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of prostate cancer is provided in the present specification. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of liver cancer is provided in the present specification. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of pancreatic cancer is provided in the present specification. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of colorectal cancer is provided in the present specification. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting.
[0109] In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-L1 inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-LI inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-LI inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting.
[0110] In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-LI inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. [[ID=,30]]In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-LI inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-LI inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting. In a further aspect, an ADC or pharmaceutical composition described herein for use in the treatment of cancer is provided in the present specification, and the pre-treatment occurs with a PD-1 or PD-LI inhibitor with or without platinum-containing chemotherapy in a neoadjuvant / adjuvant, local, advanced or metastatic setting.
[0111] In another aspect, the use of a PTK-7 ADC or pharmaceutical composition described herein for the manufacture of a medicament for the treatment of cancer is provided in the present specification. In a further aspect, the use of an ADC or pharmaceutical composition described herein for the manufacture of a medicament for the treatment of cancer is provided in the present specification. In another aspect, the use of a PTK-7 ADC or pharmaceutical composition described herein for the manufacture of a medicament for the treatment of cancer is provided in the present specification. In a further aspect, the use of an ADC or pharmaceutical composition described herein for the manufacture of a medicament for the treatment of cancer is provided in the present specification. In another aspect, the use of a PTK-7 ADC or pharmaceutical composition described herein for the manufacture of a medicament for the treatment of cancer is provided in the present specification. In a further aspect, the use of an ADC or pharmaceutical composition described herein for the manufacture of a medicament for the treatment of cancer is provided in the present specification. The cancers provided in the specification include ovarian cancer, endometrial cancer, lung cancer, head and neck cancer, and thyroid cancer. These include breast cancer, stomach cancer, kidney cancer, prostate cancer, liver cancer, pancreatic cancer, or colorectal cancer.
[0112] In a further embodiment, neoadjuvant / adjuvant, in locally progressive or metastatic environments or prior use of PD-1 or PD-L1 inhibitors with or without platinum-containing chemotherapy ADC or pharmaceutical composition described herein in the manufacture of a drug for the treatment of cancer The use of the object is provided herein.
[0113] In a further embodiment, the ADC described herein in the manufacture of a drug for the treatment of cancer Alternatively, the use of a pharmaceutical composition is provided herein, and such agent is used simultaneously with one or more antitumor agents. They are administered separately or sequentially. In a further embodiment, in the manufacture of drugs for the treatment of cancer The use of the ADC or pharmaceutical composition described herein is provided herein, and the drug The drug is administered simultaneously with, separately from, or consecutively with a PD-1 inhibitor or a PD-L1 inhibitor. .
[0114] In a further aspect, breast cancer can be HR-positive, HER2-negative, or triple-negative. It is triple-negative breast cancer (TNBC). In a further aspect, breast cancer These are mammary ducts or lobules. In a further embodiment, lung cancer is squamous non-small cell lung cancer (non-SMC). It is all-cell lung cancer (NSCLC) or non-squamous NSCLC. In further embodiments, NSCLC is metastatic or progressive. In a further aspect, lung cancer is squamous epithelium, glandular It is either small cell carcinoma. In a further aspect, lung cancer is small cell lung cancer (SCLC). In a further aspect, small cell lung cancer is metastatic or progressive. In a further aspect, the stomach In a further aspect, ovarian cancer is metastatic or It is advanced ovarian cancer. In further aspects, the ovarian cancer is serous or mucinous. In one embodiment, the ovarian cancer is the fallopian tube or peritoneum. In a further embodiment, the ovarian cancer is the fallopian tube or upper It is cutaneous. In a further aspect, ovarian cancer patients are given paclitaxel, carboplatin, and platinum. Treatment with one or a combination of systemic chemotherapy and milbetuximab sorabancin. The patient has recurrent or intractable disease after treatment.
[0115] In a further aspect, the patient or cancer has recurred or has received the following standard treatments, namely, Carboplatin and etoposit with or without atezolizumab (or durvalumab) Cisplatin and etopromazine with or without atezolizumab (or durvalumab). Pembrolizumab with or without cid, pembrolizumab, carboplatin, and pemetrexed Lolizumab, docetaxel with or without ramucirumab, bevacizumab or with The patient is refractory to one or more of the following: carboplatin and paclitaxel. .
[0116] In a further embodiment, the antitumor agent may be a chemotherapy agent including platinum-containing chemotherapy. , and / or cisplatin, carboplatin, dacarbazine, liposomal doxorubicin N, docetaxel, cyclophosphamide and doxorubicin, navelbine, eribulin, Paclitaxel, Paclitaxel protein-conjugated particle injection suspension, Ixabepirone, Ca Pecitabine, FOLFOX (leucovorin, fluorouracil, and oxaliplatin) FOLFIRI (leucovorin, fluorouracil, and irinotecan), Gemcitabine Contains , topotecan, liposomal irinotecan, pemetrexed, and cetuximab. However, this is also acceptable. In a further embodiment, the antitumor agent may be nivolumab, ipilimumab, pidilizumab, Pembrolizumab, tremelimumab, urelumab, lirilumab, atezolizumab, epacar Oncology immunotherapy agents, including those selected from the group consisting of dostat and durvalumab. This may be the case. In a further embodiment, the antitumor agent may be accompanied by atezolizumab (or durvalumab). Carboplatin and etoposide, atezolizumab (or durvalumab) without or in conjunction with Cisplatin and etoposide, pembrolizumab, carboplatin, and with or without pembrolizumab with or without pemetrexed, ramucirumab with or without Carboplatin and paclitaxel with or without docetaxel, bevacizumab could be.
[0117] Pharmaceutical composition and administration method The antibodies or ADCs described herein can be formulated as pharmaceutical compositions. The drug composition is administered, for example, orally, topically, or subcutaneously, and utilizes antibodies or ADCs to biometic effect. It is administered via one of the available routes.
[0118] Furthermore, the antibodies or ADCs provided herein, along with physiologically acceptable carriers, diluents, A pharmaceutical composition comprising one or more agents selected from the group consisting of excipients and auxiliary agents is Provided in the specifications.
[0119] The antibodies or ADCs of this disclosure, or pharmaceutical compositions containing them, are transmitted via parenteral routes (e.g., skin It may be administered by (under or intravenous). The antibodies or ADCs of this disclosure are pharmaceutically acceptable. It can be administered to patients alone in a single or multiple doses, together with a carrier, diluent, or excipient. The pharmaceutical compositions described herein are based on methods well known in the art (e.g., Rem ington:The Science and Practice of Pharm acy, 22nd ed. (2012), A. Loyd et al., Pharmac. The antibodies disclosed herein can be prepared by (eutical press) Alternatively, it may include ADC and one or more pharmaceutically acceptable carriers, diluents, or excipients.
[0120] In one embodiment, the antibody disclosed herein and one or more pharmaceutically acceptable carriers, A pharmaceutical composition comprising a dissolving agent or an excipient is disclosed herein. In some embodiments, ADC disclosed in the details and one or more pharmaceutically acceptable carriers, diluents, or excipients A pharmaceutical composition containing is disclosed herein.
[0121] definition When used herein, in the context of this disclosure (particularly in the context of the claims) The terms "a," "an," "the," and similar terms are defined otherwise in this specification. Unless otherwise specified, or unless the context clearly indicates otherwise, both singular and plural forms are used. It should be interpreted as covering the song.
[0122] As used herein, the term “to bond” means, unless otherwise specified, a chemical bond or The ability of a protein or molecule to form an attractive interaction with another protein or molecule It is intended to mean that it is determined by common methods known in the field. This brings two proteins or molecules into close proximity.
[0123] As used herein, the term “effective dose” means the amount needed to achieve the desired therapeutic outcome. This refers to the required amount (duration and means of administration). The effective amount of protein or conjugate is determined by the individual. The patient's condition, age, sex, and weight, as well as the protein or The effective amount may vary depending on factors such as the ability of the conjugate. The amount of the denjugate in which the therapeutically beneficial effects outweigh any toxic or adverse effects. .
[0124] As used herein, the terms “to treat,” “to treat,” or “to treat” This may slow, control, delay, or stop the progression of any disorder or disease disclosed herein, This refers to all processes that can improve the symptoms of a disability or disease, but not necessarily all disabilities or conditions. This does not necessarily mean that the disease symptoms have completely disappeared.
[0125] As used herein, the term "patient" refers to a human patient.
[0126] Certain abbreviations are defined as follows: "ACN" refers to acetonitrile, "AEEA" refers to 2-aminoethoxy-2-ethoxyacetic acid, and "CTC" refers to 2- "DCM" refers to dichloromethane, and "DEA" refers to dichloromethane. "DIC" refers to N,N'-diisopropylcarbodiimide, "DIPEA" refers to N,N-diisopropylethylamine, and "DBU" refers to 1,8 - refers to diazabicyclo[5.4.0]undeca-7-ene, where "DMF" is N,N-di "DTT" refers to methylformamide, while "siRNA" refers to dithiothreitol. "Ethyl acetate" refers to ethyl acetate, "EDTA" refers to ethylenediaminetetraacetic acid, and "EDCI" refers to ethylenediaminetetraacetic acid. This refers to 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, and is abbreviated as "FA". " is formic acid, "h" is time, and "Fmoc" is fluorenylmethyloxycarbonate. It refers to rubonyl, and "HEPES" is (N-2-hydroxyethylpiperazine-N'-2 - refers to ethanesulfonic acid, and "HATU" is hexafluorophosphate azabenzo "HBTU" refers to triazoletetramethyluronium, and hexafluorophosphatidyl HOBt refers to benzotriazole tetramethyluronium, and "HOBt" stands for hydroxybenzotriazole. "Nzotriazole" refers to 2-hydroxypyridine-1-oxide. "MeOH" refers to methanol, and "MTBE" refers to methyl tert-butyl ether. "Tel" refers to molecular weight cutoff, "MWCO" refers to N-hydroxy "NMP" refers to succinimide, and "OA" refers to (N-methyl-2-pyrrolidone). "ll" refers to allyloxy, "Sar" refers to sarcosine, and "Su" refers to succinyl "THF" refers to tetrahydrofuran, and "TsOH" refers to p-Tol It refers to ensulfonic acid, and "TCEP" stands for (tris(2-carboxyethyl)phosphine). ) refers to.
[0127] Embodiment Embodiments of this disclosure include, but are not limited to, the following: 1. An antibody that binds to human PTK-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain The variable region (VL) is included, and VH is the heavy chain complementarity determination region (HCDR) HCDR1, HCD VL includes R2 and HCDR3, and VL includes the light chain complementarity determining region (LCDR) LCDR1, LC Including DR2 and LCDR3, a) HCDR1 includes sequence number 4, HCDR2 includes sequence number 5, HCDR 3 contains sequence number 6, LCDR1 contains sequence number 7, and LCDR2 contains sequence number 8. LCDR3 includes, LCDR3 includes sequence number 9, b) HCDR1 includes sequence number 14, HCDR2 includes sequence number 15, HC DR3 contains sequence number 16, LCDR1 contains sequence number 17, LCDR2 contains LCDR3 includes column number 18, and array number 19, c) HCDR1 includes sequence number 24, HCDR2 includes sequence number 25, HC DR3 contains sequence number 26, LCDR1 contains sequence number 27, LCDR2 contains LCDR3 includes column number 28, and includes sequence number 29, or d) HCDR1 includes sequence number 34, HCDR2 includes sequence number 35, HC DR3 contains sequence number 36, LCDR1 contains sequence number 37, LCDR2 contains LCDR3 is an antibody containing sequence number 18, and sequence number 38. 2. HCDR1 contains sequence number 4, HCDR2 contains sequence number 5, and HCDR3 contains Column number 6 is included, LCDR1 contains sequence number 7, LCDR2 contains sequence number 8, LC The antibody according to Embodiment 1, wherein DR3 contains SEQ ID NO: 9. 3. HCDR1 contains sequence number 14, HCDR2 contains sequence number 15, and HCDR3 LCDR1 contains sequence number 16, LCDR1 contains sequence number 17, and LCDR2 contains sequence number 18. The antibody according to Embodiment 1, comprising LCDR3 containing SEQ ID NO: 19. 4. HCDR1 contains sequence number 24, HCDR2 contains sequence number 25, and HCDR3 LCDR1 contains sequence number 26, LCDR1 contains sequence number 27, and LCDR2 contains sequence number 28. The antibody according to Embodiment 1, wherein LCDR3 contains SEQ ID NO: 29. 5. HCDR1 contains sequence number 34, HCDR2 contains sequence number 35, and HCDR3 LCDR1 contains sequence number 36, LCDR1 contains sequence number 37, and LCDR2 contains sequence number 18. The antibody according to Embodiment 1, wherein LCDR3 contains SEQ ID NO: 38. 6. a) VH includes sequence number 10, and VL includes sequence number 11. b) VH includes sequence number 20, and VL includes sequence number 21. c) VH includes SEQ ID NO: 30, and VL includes SEQ ID NO: 31. d) The anti-vibration according to Embodiment 1, wherein VH includes SEQ ID NO: 39 and VL includes SEQ ID NO: 40. body. 7. The antibody includes VH containing SEQ ID NO: 10 and VL containing SEQ ID NO: 11, in an action form The antibody described in Form 6. 8. The antibody comprises VH containing SEQ ID NO: 20 and VL containing SEQ ID NO: 21, The antibody described in Form 6. 9. The antibody comprises VH containing SEQ ID NO: 30 and VL containing SEQ ID NO: 31, in an action form The antibody described in Form 6. 10. The antibody includes VH containing SEQ ID NO: 39 and VL containing SEQ ID NO: 40. The antibody described in form 6. 11. The antibody has a human IgG1 or IgG4 isotype, according to Embodiments 1 to 10. The antibody listed in any one of the following documents. 12. The antibody according to Embodiment 11, wherein the antibody has a human IgG1 isotype. 13. Residues 234 and 235 (according to EU index numbering) contain alanine. The antibody described in Embodiment 12. 14. Embodiment further comprising serine at position 265 (according to EU index numbering). The antibody described in 13. 15. The antibody contains heavy chain (HC) and light chain (LC), a) HC contains amino acids 2-441 of SEQ ID NO: 2, and LC contains amino acids 3 of SEQ ID NO: 3. b) HC contains amino acids 2-448 of SEQ ID NO: 12, and LC contains amino acids A of SEQ ID NO: 13. Contains amino acids 2-215, c) HC contains amino acids 2-447 of SEQ ID NO: 22, and LC contains amino acids A of SEQ ID NO: 23. Contains amino acids 2-215, or d) HC contains amino acids 2-444 of SEQ ID NO: 32, and LC contains amino acids A of SEQ ID NO: 33. The antibody according to Embodiment 1, comprising amino acids 2-215. 16. a) HC consists of sequence number 2, and LC consists of sequence number 3. b) HC consists of sequence number 12, and LC consists of sequence number 13. c) HC consists of sequence number 22, LC consists of sequence number 23, or d) HC consists of sequence number 32 and LC consists of sequence number 33, as described in Embodiment 15. The antibody listed. 17. Embodiment 15 or 16, in which HC is sequence number 2 and LC is sequence number 3. The antibody described above. 18. Embodiment 15 or The antibody described in 16. 19. Embodiment 15 or The antibody described in 16. 20. Embodiment 15 or The antibody described in 16. 21. The antimicrobial agent according to any one of Embodiments 1 to 20, conjugated with a cytotoxic agent. Antibody-drug conjugates (ADCs), including those containing the body. 22. Cytotoxic agents include microtubule inhibitors, topoisomerase I inhibitors, DNA damage agents, and DN A selected from the group consisting of an alkylating agent and a DNA subgroove binder, as described in Embodiment 21. ADC. 23. The embodiment according to Embodiment 21 or 22, wherein the cytotoxic agent is a topoisomerase I inhibitor. ADC. 24. The topoisomerase I inhibitor is a camptothecin analog, as described in Embodiment 23. ADC. 25. Camptothecin analogs, formula:
[0128] [ka] The ADC according to Embodiment 24, comprising the compound. 26. Camptothecin analogs, formula:
[0129] [ka] An ADC according to Embodiment 24 or 25, comprising one of the compounds. 27. Embodiments 21-2, in which the ADC further includes a linker that connects the antibody to the cytotoxic agent. The ADC listed in any one of the six items. 28. The ADC according to Embodiment 27, wherein the linker contains peptide units or sugar-cleaving units. . 29. The peptide unit is Val-Ala, Val-Cit, Phe-Lys, or Al The ADC according to Embodiment 28, including a-Ala-Asn. 30. The ADC according to Embodiment 29, wherein the peptide unit comprises Val-Ala. 31. The ADC according to Embodiment 29, wherein the peptide unit contains Val-Cit. 32. The ADC is, formula:
[0130] [ka] An ADC according to any one of embodiments 21 to 30, comprising the compound. 33. The sugar-cleaving unit is given by the formula:
[0131] [ka] The ADC according to Embodiment 28, comprising the compound. 34. The ADC is, formula:
[0132] [ka] The ADC according to Embodiment 33, comprising the compound. 35. The linker further comprises a hydrophobic masking group, any one of embodiments 21 to 34. The ADC described above. 36. The hydrophobic masking group is selected from polysarcosine or polyethylene glycol. The ADC described in embodiment 35. 37. In embodiment 35 or 36, the hydrophobic masking group is in a branched arrangement on the linker. The ADC described. 38. Hydrophobic masking group, formula:
[0133] [ka] It is a polysarcosine, where k is an integer between 6 and 12, and X1 is H, OH, or NH. The ADC according to embodiment 36 or 37, which is 2. 39. The ADC according to Embodiment 38, wherein k is 10. The ADC according to Embodiment 38, wherein 40.k is 12. 41. The linker further includes a connection unit as described in any one of embodiments 27 to 40. ADC. 42. The unit of connection is, formula:
[0134] [ka] The ADC according to Embodiment 41, wherein the compound is such that z is 1 to 5 in the formula. 43. The unit of connection is, formula:
[0135] [ka] The ADC according to Embodiment 41, wherein the compound is such that z is 1 to 5 in the formula. 44. The unit of connection is, formula:
[0136] [ka] The ADC according to Embodiment 41, wherein the compound is such that z is 1 to 5 in the formula. 45. The unit of connection is:
[0137] [ka] The ADC according to Embodiment 41, wherein the compound is such that z is 1 to 5 in the formula. 46. Antibody-drug conjugate (ADC), wherein the ADC is given by formula:
[0138] [ka] It is one of the compounds, During the ceremony, Ab is the antibody described in any one of Embodiments 1 to 21. n is approximately 1 to 16, and is an ADC. 47. An ADC according to embodiment 46, wherein n is approximately 2 to 12. 48. An ADC according to embodiment 46, wherein n is approximately 2 to 8. 49. ADC is, formula:
[0139] [ka] ADC according to any one of embodiments 46 to 48, which is a compound of the above. 50. ADC is, formula:
[0140] [ka] ADC according to any one of embodiments 46 to 48, which is a compound of the above. 51. An ADC according to any one of embodiments 46 to 50, wherein n is approximately 2. 52. An ADC according to any one of embodiments 46 to 50, wherein n is approximately 4. 53. An ADC according to any one of embodiments 46 to 50, wherein n is approximately 6. 54. An ADC according to any one of embodiments 46 to 50, wherein n is approximately 8. 55. The connection to the antibody occurs via one or more cysteine thiol groups of the antibody. ADC as described in any one of the application methods 46 to 54. 56. Each of the cysteine molecules is a native cysteine in the hinge region of the antibody. The ADC described in Embodiment 55. 57.Ab contains HC with amino acids 2-441 of SEQ ID NO: 2 and LC with amino acids 3. An ADC according to any one of embodiments 46 to 56, comprising and where n is approximately 8. 58. Ab includes HC consisting of SEQ ID NO: 2 and LC consisting of SEQ ID NO: 3. ADC as described in Form 57. 59.Ab contains HC with amino acids 2-448 of SEQ ID NO: 12 and ami of SEQ ID NO: 13 One of embodiments 46 to 56, comprising LC containing 2 to 215 no acids, wherein n is approximately 8. One ADC listed. 60.Ab includes HC, which is sequence number 12, and LC, which is sequence number 13. The ADC described in Embodiment 59. 61.Ab contains HC with amino acids 2-447 of SEQ ID NO: 22 and ami of SEQ ID NO: 23 One of embodiments 46 to 56, comprising LC containing 2 to 215 no acids, wherein n is approximately 8. One ADC listed. 62. Ab includes HC, which is sequence number 22, and LC, which is sequence number 23. The ADC described in Embodiment 61. 63.Ab contains amino acids 2-444 of SEQ ID NO: 32 and amino acids 2-2 of SEQ ID NO: 33. An embodiment of any one of embodiments 46 to 56, which includes LC containing 15, and n is approximately 8. ADC. 64. Ab includes HC, which is sequence number 32, and LC, which is sequence number 33. The ADC described in Embodiment 63. 65. An antibody according to any one of Embodiments 1 to 20, and one or more pharmaceutically acceptable A pharmaceutical composition comprising a carrier, a diluent, or an excipient. 66. An ADC according to any one of embodiments 21 to 64, and one or more pharmaceutically acceptable A pharmaceutical composition comprising a carrier, diluent, or excipient. 67. To a patient who requires treatment for cancer, any of embodiments 21 to 64 in an effective dose. A method of treating cancer, comprising administering one of the ADCs described herein. 68. Cancers include ovarian cancer, lung cancer, breast cancer, stomach cancer, kidney cancer, prostate cancer, and liver cancer. The method according to embodiment 67, wherein the cancer is colorectal cancer. 69. Administer PD-1 inhibitors or PD-L1 inhibitors simultaneously, separately, or sequentially. The method according to embodiment 67 or 68, further comprising the above. 70. ADC according to any one of embodiments 21 to 64 for use in therapy . 71. The embodiment described in any one of embodiments 21 to 64 for use in the treatment of cancer. ADC. 72. Cancers include ovarian cancer, lung cancer, breast cancer, stomach cancer, kidney cancer, prostate cancer, and liver cancer. ADC for use according to Embodiment 71, or colorectal cancer. 73. ADCs are administered simultaneously, separately, or sequentially with PD-1 inhibitors or PD-L1 inhibitors. A for use as described in any one of embodiments 21 to 64, administered in combination with DC. 74. Therapy of cancer comprising an ADC described in any one of the effective dose embodiments 21 to 64. Pharmaceutical compositions for use in [location / area]. 75. Cancers include ovarian cancer, lung cancer, breast cancer, stomach cancer, kidney cancer, prostate cancer, and liver cancer. A composition for use according to Embodiment 74, which is a colorectal cancer. 76. PD-1 inhibitors or PD-L1 inhibitors may be administered simultaneously, separately, or in combination in sequence. The composition according to embodiment 74 or 75, which is administered by means of [unclear]. 77. Any one of embodiments 21 to 64 for the manufacture of a drug for the treatment of cancer. Use of the ADC as described. 78. Cancers include ovarian cancer, lung cancer, breast cancer, stomach cancer, kidney cancer, prostate cancer, and liver cancer. The use described in Embodiment 77, which is for colorectal cancer. 79. Embodiment 77 or the embodiment in which the drug further comprises a PD-1 inhibitor or a PD-L1 inhibitor. Use as described in 78. 80. Condensing the antibody described in any one of Embodiments 1 to 20 with the linker payload A method for preparing an ADC, including terminating it. 81. Linker-payload, formula:
[0141] [ka] The method according to Embodiment 80, comprising the compound. 82. Linker-payload, formula:
[0142] [ka] The method according to Embodiment 80, comprising the compound. 83. A method for producing an ADC, the antibody according to any one of Embodiments 1 to 20. The formula:
[0143] [ka] A method comprising contacting a compound with the compound. 84. Before contact, the antibody is reduced with a reducing agent to produce reduced PTK-7 antibody. The method according to embodiment 83, further comprising producing [Examples]
[0144] Example 1: Preparation of PTK-7 antibody The CDRs, variable regions, full heavy chain and light chain amino acid sequences of antibodies 1-4, and the combination of these. The nucleotide sequences listed below are listed in the section titled "Amino Acids and Nucleotide Sequences". In addition, the CDR, light chain, heavy chain, light chain variable region, and heavy chain variable region of antibodies 1-4 are listed. The sequence numbers for each are shown in Tables 1 and 2.
[0145] The anti-PTK-7 antibodies of this disclosure, including but not limited to antibodies 1-4, are essentially The antibodies can be expressed and purified as shown below. Antibodies 1-4 can be expressed in the transgenic system. These are fully human antibodies produced through immunization.
[0146] Antibodies were synthesized and purified using a well-known method. The antibody heavy chain and light chain variable regions were encoded. The gene is expressed and purified using PBv2-pKlig according to standard procedures. Cloned into ht and pPB-huIgG1(AAS) vectors. The light chain was human cut. The heavy chain is human IgG1-AAS:L234A based on the EU index number. It is / L235A / D265S.
[0147] Suitable host cells, such as Chinese hamster ovary cells (CHO), contain two vectors. When a ter is used, an antibody with a specified HC:LC ratio, or both heavy and light chains, is used. A single vector system that secretes antibodies, temporarily or stably in an expression system. It can be transfected. The clarified medium on which the antibody has been secreted is a commonly used technique. It can be purified using the following methods. Initial capture is performed using conventional methods and buffer systems. In-A column chromatography is used to subsequently analyze host cell proteins and high molecular weight species. As a finishing step for removal, ion exchange and / or hydrophobic interaction chromatography The product can be immediately frozen at, for example, -80°C, or at 2-8°C for several months. It can be stored for a month.
[0148] [Table 3]
[0149] [Table 4]
[0150] [Table 5]
[0151] Example 2: Fabrication of PTK-7 ADC Synthesis of PSAR-glucuronide-exatecan-containing linker-payload of formula XIV
[0152] [ka]
[0153] To prepare for conjugation to PTK antibodies in this disclosure, the linker-pe of formula XVI Irod is a polysarcosine (PSAR) compound, 4-beta-glucuronide-3-nitrate Low-octapamine compounds, exatecan compounds, and maleimide-propionyl compounds Synthesized from a precursor or intermediate containing [the specified compound]. The linker-payload is described in International Publication No. 20190. It can be synthesized using the methods disclosed in Patent No. 81455 and Patent No. 2022207699. ru.
[0154] PSAR intermediate: FmocNH-PEG2-Glu(Su)-PSAR10-NH 2
[0155] [ka]
[0156] Scheme 1
[0157] [ka]
[0158] PSAR intermediates can be prepared using Scheme 1. Polysarcosine tree Fatty surface synthesis using commercially available Fmoc-Sar-Sar-OH dipeptoid building blocks This is carried out using a repeating procedure for the synthesis of submonomers for Rink amides having the following characteristics. Unless otherwise specified, all reactions are carried out at room temperature.
[0159] Rink amide pre-filled with the first Fmoc-sarcosine residue was used as the starting material. Rink amide pre-filled with Fmoc-sarcosine is added to 20% piperidopropyl alcohol in DMF. Treat with (1 mL per 100 mg of resin) at room temperature for 15 minutes twice. Then, DM the resin. Wash with F (4 times) and DCM (4 times). Add DMF (1 m³ per 100 mg of resin) to the resin. Fmoc-Sar-Sar-OH (3 equivalents), HATU (2.9 equivalents), and D in L) A solution of IPEA (6 equivalents) was added. The reaction vessel was stirred for 2 hours, and the resin was treated with DMF (4 times). Then wash with DCM (4 times). The resin is treated with 20% piperidine in DMF (per 100 mg of resin). Treat with 1 mL each at room temperature for 15 minutes twice. Then, treat the resin with DMF (4×) and DC. Washed with M(4×), Rink resin having n=3 polysarcosine oligomers is obtained. .
[0160] By alternating between the bromoacetylation step and the amine substitution step, the desired length can be obtained. Until it is possible, the submonomer synthesis procedure is used to extend n=3 polysarcosine oligomers. The process is carried out. The bromoacetylation step is carried out using 10 equivalents of bromoacetic acid and 13 equivalents of DMF. By adding diisopropylcarbodiimide (2 mL per 100 mg of resin) Implement the following: Stir the mixture for 30 minutes, drain, and wash with DMF (4 times). Amine replacement process For this purpose, 40% (wt) methylamine in aqueous solution (1.5 mL per 100 mg of resin) Add the mixture, shake the container for 30 minutes, drain, and wash with DMF (4 times) and DCM (4 times). ru.
[0161] Once the desired polysarcosine oligomer length is reached (e.g., PSAR 10-mer), Orthogonal chemical functionalization is performed. Following orthogonal chemical functionalization, an Fmoc protected amino acid group or other Final capping may be performed with the Fmoc protective group. The Fmoc protective group may be applied before or after resin cutting. It can be removed.
[0162] Polysarcosine is composed of glutamic acid and amino-3,6-dioxaoctane, as follows: It can be functionalized with acid. Fmoc-Glu(O) in DMF (1 mL per 100 mg of resin) All)-OH (3 equivalents), HATU (2.9 equivalents), and DIPEA (6 equivalents) are added to Ri Add to nk resin. Stir the reaction vessel for 90 minutes, then add DMF (4 times) and DCM (4 times). Wash with (times). Then, soak the resin in 20% piperidine in DMF for 15 minutes at room temperature (resin 10 Treat twice with 1 mL per 0 mg. Wash the resin with DMF (4 times) and DCM (4 times). Next, Fmoc-amino-3,6-di in DMF (1 mL per 100 mg of resin) Oxaoctanoic acid (3 equivalents), HATU (2.9 equivalents), DIPEA (6 equivalents) for 1 hour Coupling was performed. The resin was washed with DMF (4 times) and DCM (4 times). 0.25 equivalents Pd(PPh3)4 and 20 equivalents of phenylsilane (gently stirred under an argon stream) The alloc protecting group is removed by two 30-minute treatments with a DCM solution containing ). Next, the resin is washed with DMF (5 times) and DCM (5 times). N-hydroxysulfate Synimide (N-hydroxysuccinimide, NHS) ester, 50 equivalents of DIC and 60 equivalents DM containing a certain amount of N-hydroxysuccinimide (1.5 mL per 100 mg of resin) Treatment with solution F for 90 minutes introduces the carboxylic acid side chain of the final polysarcosine compound. Next, the resin is washed with DMF (4 times) and DCM (4 times). Then, the final polymer The sarcosine compound is cleaved from the resin (100% TFA, twice, 30 minutes).
[0163] 4-Beta-glucuronide-3-nitrooctopamine intermediate: (2S,3R,4S,5 S,6S)-2-(4-(2-((tert-butoxycarbonyl)amino)-1-(( (4-Nitrophenoxy)carbonyl)oxy)ethyl)-2-Nitrophenoxy)-6 -(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate Tate
[0164] [ka]
[0165] Scheme 2
[0166] [ka]
[0167] 4-Beta-glucuronide-3-nitro-octopamine intermediate 4-Beta-glucuronide do-3-nitro-octopamine intermediate: (2S,3R,4S,5S,6S)-2-(4- (2-((tert-butoxycarbonyl)amino)-1-(((4-nitrophenoxy )carbonyl)oxy)ethyl)-2-nitrophenoxy)-6-(methoxycarbonyl) ) Tetrahydro-2H-pyran-3,4,5-triyltriacetate is used in scheme 2. It can be prepared using this method.
[0168] The octopamine or octopamine intermediate used in this method is a racemic mixture, It can be obtained as an enantiopure compound. The racemic mixture is enantiopure To obtain the compound, it can be subjected to chiral separation known in the art.
[0169] Suspend octopamine (±) hydrochloride (1690 mg, 11 mmol) in 4 mL of distilled water. Cool the flask to 0°C and slowly add 4 mL of pre-cooled 65% nitric acid solution. The reaction mixture is maintained at 0°C for 20 minutes, and mononitration is evaluated by HPLC. Transfer the octopamine precursor to a pre-cooled 250 mL Erlenmeyer flask and adjust the pH to 8-9. Slowly neutralize with saturated NaHCO3 solution at 0°C until the value is reached. Then, add 30 mL of chlorine solution. Oxane is added, followed by Boc2O (7202 mg / 13.2 mmol). Allow the reaction mixture to reach room temperature and stir overnight. Then, dilute the reaction mixture with ԅ and saturate it. Wash three times with enoic acid solution and once with saturated NaCl solution. Dry the organic phase on MgSO4. The product was filtered, evaporated under vacuum, and then chromatographed using silica gel. It is refined by (petroleum ether / siRNA, gradient 70:30~20:80), Nonitrated octopamine precursor: tert-butyl(2-hydroxy-2-(4-hydro Xy-3-nitrophenyl)ethyl)carbamate is obtained. Then, the obtained mononitro The octopamine precursor is subjected to chiral separation before further synthesis steps are carried out.
[0170] Racemic tert-butyl(2-hydroxy-2-(4-hydroxy-3-nitrophenate) Chiral separation of ethyl carbamate is performed using MPLC (Medium Pressure Liquid Chromatography). The mobile phase consists of DCM±0.2%(v / v)EtOH (uniform concentration gradient) and DCM±0 The procedure is carried out using a sample solvent of 0.2% (v / v) EtOH. To determine the absolute configuration, The phenolic positions of both enantiomers are in 1.2 molar equivalents of 4-nitroglycerin in anhydrous THF. Esterilize with 2 molar equivalents of iodine chloride and triethylamine. The compound is then esterified with silica. Chromatography in gel (petroleum ether / SiO, gradient 90:10~10:90) Purified by 4-(2-((tert-butoxycarbonyl)amino)-1-Hyd Roxyethyl)-2-nitrophenol 4-nitrobenzoate is obtained. Enantiomer The absolute configuration (dissolve in a 1:1 mixture of heptane / dichloromethane beforehand and slowly for 3 weeks) The formation of crystals (induced by evaporation) is confirmed by X-ray crystallography.
[0171] During the round-bottom flush, Ag2CO3 (1500 mg, 5.4 mmol) and 1,1,4, 7,10,10-Hexamethyltriethylenetetramine (251 mg, 1.1 mmol) Suspend in 4 mL of anhydrous acetonitrile and stir at room temperature for 2 hours. Enantiopurine t ert-butyl(2-hydroxy-2-(4-hydroxy-3-nitrophenyl)ethyl) ) Carbamate (292 mg, 0.98 mmol) and 1-bromo-2,3,4-tri- O-acetyl-α-D-glucuronide methyl ester (583 mg, 1.46 mmol) Add at 0°C and stir the solution mixture at room temperature for 4 hours. Then filter the reaction product through diatomaceous earth. Dilute with ethyl acetate, wash three times with saturated citric acid solution, and once with saturated NaCl solution. The phase is dried on MgSO4, filtered, and evaporated under vacuum to obtain the crude product. Chromatography in silica gel (petroleum ether / toluene, 70:30~30:7 Purified by a gradient of 0, (2S,3R,4S,5S,6S)-2-(4-(2-( (tert-butoxycarbonyl)amino)-1-hydroxyethyl)-2-nitrophen (Noxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-tri Obtain yltriacetate.
[0172] (2S,3R,4S,5S,6S)-2-(4-(2-((tert-butoxycarb (Nyl)amino)-1-hydroxyethyl)-2-nitrophenoxy)-6-(Methoxycarbon) Rubonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (334 mg / 0.54 mmol) and 4-nitrophenyl chloroformate (219 mg / 1. Dissolve 0.9 mmol) in 6 mL of dry DCM at 0°C. Anhydrous pyridine (112 mg, Add 1.41 mmol) and stir the mixture at room temperature for 30 minutes. Dilute the reaction mixture to 0.45 μm. Filtered with a PTFE filter, and chromatography with silica gel (petroleum ether / Et Purified by OAc (gradient 85:15~30:70), (2S, 3R, 4S, 5S) ,6S)-2-(4-(2-((tert-butoxycarbonyl)amino)-1-((( 4-Nitrophenoxy)carbonyl)oxy)ethyl)-2-Nitrophenoxy)-6- (Methoxycarbonyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate Obtain the ticket.
[0173] 4-Beta-glucuronide-3-nitro-octopamine-exatecan intermediate:(2S) ,3R,4S,5S,6S)-2-(4-(2-amino-1-((((1R,9R)-9 -ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3 ,9,10,13,15-Hexahydro-1H,12H-benzo[de]pyrano[3', 4':]6,7]Indrizino[1,2-b]Quinoline-1-yl)Carbamoyl)Oxy (C)ethyl)-2-nitrophenoxy)-3,4,5-trihydroxytetrahydro-2 H-pyran-2-carboxylic acid
[0174] [ka]
[0175] Scheme 3
[0176] [ka]
[0177] Using Scheme 3, the 4-beta-glucuronide-3-nitro-octopamine intermediate was used. It is then conjugated to exatecan, and 4-beta-glucuronide-3-nitro-octo Pamine-exatecan intermediate: (2S,3R,4S,5S,6S)-2-(4-(2-A MINO-1-((((1R,9R)-9-ethyl-5-fluoro-9-hydroxy-4-methyl Tyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,1 2H-benzo[de]pyrano[3',4':6,7]indridino[1,2-b]quinori N-1-yl)carbamoyl)oxy)ethyl)-2-nitrophenoxy)-3,4,5 -Trihydroxytetrahydro-2H-pyran-2-carboxylic acid can be obtained.
[0178] 101 mg (0.13 mmol) of 4-beta-glucuronide-3-nitro-octopa Min intermediate (2S,3R,4S,5S,6S)-2-(4-(2-((tert-butoki (Cicarbonyl)amino)-1-(((4-nitrophenoxy)carbonyl)oxy)eth (L)-2-nitrophenoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyra n-3,4,5-triyltriacetate, 0.14 mmol of exatecan mesylate, and 18 mg (0.13 mmol) of HOBt in anhydrous DMF / pyridine 85:15 ( Dissolve in 1 mL of the v / v mixture. Add 16.7 mg (0.13 mmol) of DIPEA. Add the mixture. Stir the reaction mixture at 40°C for 2 hours, and evaporate the volatile substances under reduced pressure. The crude residue is then shrunk. Chromatography using Licagel (DCM / MeOH gradient 99:1~95:5) The intermediate compound is then prepared and subjected to deprotection.
[0179] 144 mg (0.106 mmol) of this intermediate compound is dissolved in 3 mL of MeOH (7) at 0°C. Dissolve in 5:25). Add LiOH monohydrate (44.5 mg, 1.06 mmol) to water (0 Dissolve in 0.4 mL and add to the reaction vessel. After stirring, add the mixture to acetic acid (83 mg, 1.4 mL). Neutralize with (mol) and concentrate under reduced pressure. Redissolve the resulting crude product in TFA / DCM solution. Stir. Evaporate volatile substances under reduced pressure, collect the crude residue, and purify using HPLC. (2S,3R,4S,5S,6S)-2-(4-(2-amino-1-((((1 R,9R)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-di Oxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de] Pirano[3',4':]6,7]Indrizino[1,2-b]Quinoline-1-yl)Cal Bamoyl(oxy)ethyl(2-nitrophenoxy)-3,4,5-trihydroxy( Trahydro-2H-pyran-2-carboxylic acid is obtained.
[0180] Functionalized PSAR-4-beta-glucuronide-3-nitro-octopamine-exateca To obtain the intermediate, the PSAR intermediate and 4-beta-glucuronide-3-nitro-o Ctopamine-exatecan intermediate conjugation
[0181] [ka]
[0182] Scheme 4
[0183] [ka]
[0184] PSAR intermediate and 4-beta-glucuronide-3-nitro-octopamine-exate The Kan intermediate is conjugated using Scheme 4 to functionalize PSAR-4-beta. -Glucuronide-3-nitro-octopamine-exatecan intermediate can be obtained.
[0185] 100 mg (0.081 mmol) of PSAR intermediate and 51 mg (0.061 mmol) l) 4-beta-glucuronide-3-nitro-octopamine-exatecan intermediate is not Dissolve in water DMF. Add 41 mg (0.405 mmol) of triethylamine and react. Stir the reaction mixture at room temperature for 30 minutes. After the complete transformation of the reactants is evaluated by HPLC, To obtain an 8% (v / v) piperidine solution in DMF, add piperidine to the reaction vial. Add directly. Then, HPLC is performed until the entire Fmoc deprotection is observed. Stir the mixture at room temperature for 5-10 minutes. Add the reaction mixture to 10% TFA in water / ACN 1:1 (v / v). Slowly neutralize with solution and purify using HPLC to obtain functionalized PSAR-4-beta-g Obtain the lucuronide-3-nitro-octopamine-exatecan intermediate.
[0186] Linker-payload of formula XIV: (2S,3S,4S,5R,6S)-6-(4-( (3S,9S)-40-amino-9-(2-(2-(2-(3-(2,5-dioxo-2 ,5-dihydro-1H-pyrrole-1-yl)propanamide)ethoxy)ethoxy) Cetoamide)-1-(((1S,9S)-9-ethyl-5-fluoro-9-hydroxy- 4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1 H,12H-benzo[de]pirano[3',4':6,7]indrizino[1,2-b] Quinoline-1-yl)amino)-11,14,17,20,23,26,29,32,3 5,38-decamethyl-1,6,10,13,16,19,22,25,28,31,3 4,37,40-Tridecaoxo-2-oxa-5,11,14,17,20,23,2 6,29,32,35,38-Undekazatetracontan-3-yl)-2-nitro Phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
[0187] [ka]
[0188] Scheme 5
[0189] [ka]
[0190] The linker-payload of formula XIV is maleimidepropionic acid using scheme 5. N-hydroxysuccinimide ester and functionalized PSAR-4-beta-glucuron By conjugating the do-3-nitro-octopamine-exatecan intermediate It can be prepared.
[0191] N-hydroxysuccinimide maleimidopropionate and functionalized PSAR -4-beta-glucuronide-3-nitro-octopamine-exatecan intermediate, anhydrous Dissolve in DMF (0.1M maleimide compound). 1.56 mg (0.015) Add triethylamine and continue until complete conversion of the reactants is observed by HPLC. The reaction mixture was stirred for 2 hours. Then, the reaction mixture was prepared as 1% TFA aqueous solution / ACN 1:1 (v / Dilute with v) and purify using HPLC preparative method 6 to obtain the Linker-Peyrow of formula XIV. Obtain the "do".
[0192] Synthesis of PSAR-Val-Ala-exatecan-containing linker-payload of formula XV
[0193] [ka]
[0194] To prepare for conjugation to PTK antibodies in this disclosure, linker-pay of formula XV Load, polysarcosine (PSAR) compounds, valine-alanine compounds, exatecan Synthesized from a precursor or intermediate containing the compound and maleimide compound. Linker-peyro The code is disclosed in International Publication No. 2019081455 and No. 2022207699. It can be synthesized using the method described.
[0195] (S)-32-(3-(((S)-2-(4-((S)-2-((S)-2-Acetami (3-methylbutanamide)propanamide)phenyl)-2-((((1S,9S) -9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2 ,3,9,10,13,15-Hexahydro-1H,12H-benzo[de]pyrano[3 ',4':6,7]Indrizino[1,2-b]Quinoline-1-yl)Carbamoyl)O Xy(ethyl)amino)-3-oxopropyl)-45-(2,5-dioxo-2,5- Dihydro-1H-pyrrole-1-yl)-3,6,9,12,15,18,21,24, 27,30-decamethyl-4,7,10,13,16,19,22,25,28,31, 34,43-Dodecaoxo-36,39-Dioxa-3,6,9,12,15,18,2 1,24,27,30,33,42-Dodecazapentatetracontanoic acid
[0196] Scheme 6
[0197] [ka]
[0198] Step 6.1a
[0199] [ka]
[0200] tert-butyl((S)-2-(4-((S)-2-aminopropanamide)phen (L)-2-hydroxyethyl)carbamate Fmoc-Ala-OH (473.5g, 1.52mmol, 1.3eq) in DCM It was solubilized in (3000 mL). The solution was cooled to 10°C. HOPO(154.2 g) (1.39 mmol, 1.6 equivalents) and EDCI (291.3 g, 1.88 mmol, 1 0.2 equivalents were added under N2 conditions. After stirring at 10°C for 0.5 hours, tert-butyl ( S)-(2-(4-aminophenyl)-2-hydroxyethyl)carbamate (295. (0g, 1.17 mmol, 1 equivalent) was added and stirred at 15°C for 1 hour. DEA (1.6 7 kg (19.5 equivalents) was added dropwise over 1 hour. After the addition was complete, the mixture was left at 15°C for 1 hour. The mixture was then stirred at 0°C for 14 hours. The mixture was concentrated under vacuum (35°C). Chromatography Graphics: Eluent: n-heptane / DCM = 10 / 1~1 / 10, DCM / THF = 10 / 1~1 / 10, Eluent: THF / MeOH = 100 / 1~10 / 1. Evaporate under reduced pressure. Subsequently, the title compound (270.0 g, 71%) was obtained.
[0201] Step 6.1b
[0202] [ka]
[0203] 2,5-Dioxopyrrolidine-1-ylacetyl-L-valinate Soluble Ac-Val-OH (60g, 0g, 1 equivalent) in DCM (1200mL), Next, NHS (52.1 g, 1.2 equivalents) was added and stirred at 0°C for 18 hours. DCC ( 93.3g (1.2 equivalents) was added all at once, and the mixture was stirred at 0°C for 18 hours. Filtered and 3 times in DCM. Washed once and evaporated to half its volume (40°C). Cooled to 30°C and stirred for 1 hour. Filtered. Wash the cake with 1:2 DCM / MTBE (50 mL) and 2 times under vacuum (30°C). The mixture was dried for 2 hours. The title compound (86.7 g, 89.8%) was obtained as a solid.
[0204] Process 6.2
[0205] [ka]
[0206] tert-butyl((S)-2-(4-((S)-2-((S)-2-acetamide-3 -Methylbutanamide)propanamide)phenyl)-2-hydroxyethyl)carbamate te tert-butyl((S)-2-(4-((S)-2-aminopropanamide)phen (L)-2-hydroxyethyl)carbamate (17.0g, 52.6mmol, 1 equivalent) It was solubilized in THF (250 mL). The temperature was adjusted to 10-20°C. 2,5-di Oxopyrrolidine-1-ylacetyl-L-valinate (13.47g, 52.6mmo) I added 1.0 equivalent. Stirred at 10-20°C for 3 hours. Adjust the temperature to -5-5°C. The reaction mixture was filtered, and the filtered cake was dried under N2 flow at 10-20°C for 14 hours. The filtered cake was placed in THF (100 mL) and H2O (350 mL) was added. The temperature was set to 1 The mixture was adjusted to 0-20°C and stirred for 13 hours. It was filtered, and the filtered cake was washed with H2O (60 mL). The sample was purified. The filtered cake was dried at 40-50°C for 54 hours. Title compound (21g, 86%) ) was obtained as a solid.
[0207] Process 6.3
[0208] [ka]
[0209] tert-butyl((S)-2-(4-((S)-2-((S)-2-acetamide-3 -Methylbutanamide)propanamide)phenyl)-2-(((4-nitrophenoxy Carbonyl oxyethyl carbamate Under N2 conditions, tert-butyl((S)-2-(4-((S)-2-((S)-2-acete Toamido-3-methylbutanamide)propanamide)phenyl)-2-hydroxyethyl Carbamate (100.0g, 215mmol, 1 equivalent) in anhydrous DMF (900g) It was dissolved in [a solution]. The temperature was adjusted to 5-15°C and stirred for 5-15 minutes. Bis(4-nitro) carbonate Phenyl (132.0g, 434 mmol, 2.0 equivalents) was added. DIPEA (83 0.5g (3 equivalents) was added dropwise under N2 conditions at 5-15°C. The temperature was then adjusted to 15-25°C. Stirred for 4-6 hours. Bis(4-nitrophenyl) carbonate (6.5g, 21mmol, 0. (10 equivalents) was added further. Stirred under N2 at 15-25°C for 1-2 hours. SiO( Add 4400g of (and 4500g of H2O). Stir at 15-25°C for 10-30 minutes. It was left to stand for 10-30 minutes. The organic layer was separated and saved for later. HCl (44 Add 00g) to the aqueous layer and stir at 15-25°C for 10-30 minutes. Let stand for 10-30 minutes. The previous organic layer was added again, followed by the addition of 10% NaCl aqueous solution (4000g). The mixture was stirred at 5-25°C for 10-30 minutes. It was allowed to stand for 10-30 minutes. The aqueous layer was separated. (Anhydrous) Na2SO4 (200g) was added to the organic layer. The temperature was adjusted to 15-25°C, and 10-30 The mixture was stirred for several minutes. It was filtered, and the filtered cake was washed with HCl (200g). The layer was collected. The mixture was then concentrated to about half its original volume at a temperature below 40°C. The temperature was adjusted to 30-40°C and stirred for 10-30 minutes. Mixed. n-heptane (1400g) was added dropwise over 0.5 hours at 30-40°C. The temperature was adjusted to 10-20°C and stirred for 3-6 hours. Filtered, and the filtered cake was mixed with EtOA in a 1:2 ratio. Washed with c / n-heptane (500g). Filtered cake under N2 with alkyl phosphate (900g). (0g) was added, the temperature was adjusted to 30-40°C, and stirred for 10-30 minutes. n-heptane ( 1400g was added dropwise over 0.5 hours at 30-40°C. The temperature was then adjusted to 10-20°C. Stirred for 3-6 hours. Filter and add the filtered cake to a 1:2 toluene / n-heptane (50%) solution. Washed (0g). The filtered cake was dried at 30-40°C for 20-30 hours. Title compound (119g, 88%) was obtained as a solid.
[0210] Process 6.4
[0211] [ka]
[0212] (S)-1-(4-((S)-2-((S)-2-acetamide-3-methylbutaneamide (D)propanamide)phenyl)-2-aminoethyl((1S,9S)-9-ethyl-5 -Fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10, 13,15-Hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7 Indrizino[1,2-b]quinoline-1-yl)carbamate Mesylic acid in DMF (1504g) and pyridine (392g) under N2 conditions at 10-20°C In a suspension of exatecan (100.0 g, 188.1 mmol, 1 equivalent), tert- Chil((S)-2-(4-((S)-2-((S)-2-acetamido-3-methylbuta (Panamide)propanamide)phenyl)-2-(((4-nitrophenoxy)carbonyl Oxy)ethyl)carbamate (142.2g, 225.8mmol, 1.2 equivalents), HOBt (25.42g, 188.1mmol, 1.0 equivalent) and DIPEA (48.6 (3g, 376.3 mmol, 2.0 equivalents) was added. Incubated under N2 at 10-20°C for 4-6 hours. The mixture was stirred. The temperature was adjusted to 15-25°C. DCM (8000g) and 10% Na2CO 3. The aqueous solution was added and stirred for 10-30 minutes. After standing for 10-30 minutes, the aqueous layer was separated. In the organic layer, add DMF (450g), H2O (1000g), and 10% citric acid aqueous solution (15 Add 0.0g and adjust the pH to 6-8. Stir at 10-20°C for 5-10 minutes. 2. Leave it for 5-30 minutes and separate the aqueous layer. Add anhydrous Na2SO4 (500g) to the organic layer. The mixture was added and stirred at 10-20°C for 10-30 minutes. It was filtered and washed with DCM (500g). The filtrate was concentrated at ≤30°C. This mixture was added dropwise to MTBE (3000g), and the temperature was adjusted. The temperature was adjusted to 10-20°C. The mixture was stirred under N2 at 10-20°C for 0.5-1 hour. The mixture was filtered. After passing through the period, it was washed with MTBE (800g). DCM was added to the filtered cake under N2 conditions, and the temperature was adjusted. The temperature was adjusted to -10 to 0°C and stirred for 5 to 15 minutes. TFA (459g) was added over 0.5 hours. It was added dropwise. It was stirred under N2 at -10 to 0°C for 1 to 4 hours. Then TFA (30g) was added dropwise. The mixture was stirred under N2 at -10 to 0°C for 0.5 to 2 hours. Then, TFA (30g) was added dropwise. The mixture was stirred under N2 at -10 to 0°C for 0.5 to 2 hours. The reaction solution was then mixed with MTBE (14000g). Add the solution of ) and n-heptane (3415g) dropwise over 0.5 hours, and cool to -10~5°C. The mixture was filtered and washed with MTBE (800g). The filtered cake was 25-3 The compound was dried at 5°C for 10-15 hours. The title compound (139 g, 90%) was obtained as a solid.
[0213] Scheme 7
[0214] [ka]
[0215] Process 7.1
[0216] [ka]
[0217] (S)-14-(3-((2,5-dioxopyrrolidine-1-yl)oxy)-3-O Xopropyl)-1-(9H-Fluoren-9-yl)-16,19,22,25,28 ,31,34,37,40,43-decamethyl-3,12,15,18,21,24,2 7,30,33,36,39,42-dodecaoxo-2,7,10-trioxa-4,1 3,16,19,22,25,28,31,34,37,40,43 - Dodecazapenta Tetracontane-45-acid 1) DCM is mixed with CTC resin (12.80g, 10.00 mmol, 0.78 mmol / g) and Fmoc-Sar-OH (2.48 g, 8.00 mmol, 0.80 equivalents), N2 was added while bubbling. 2) Add DIPEA (4.00 equivalents) dropwise and mix for 2 hours. 3) Add MeOH (13 mL) and mix for 30 minutes. 4) Drain the fluid and wash five times with DMF. 5) Add 20% piperidine / DMF and allow to react for 30 minutes. 6) Drain the fluid and wash five times with DMF. 7) Add the Fmoc-amino acid solution, mix for 30 seconds, then add the activation buffer. N2 bubbling lasted for about an hour. 8) Steps 4-7 above were repeated for the coupling of the following amino acids.
[0218] [Table 6]
[0219] The coupling reaction was monitored by a ninhydrin test, and the resin was washed five times with DMF. Ta.
[0220] Peptide cleavage and purification: 1) Add cleavage buffer (1% TFA, 99% DCM) to a flask containing the side-chain protective peptide. It was added at room temperature. 2) The solution was filtered and the filtrate was collected. 3) The solvent was removed under vacuum to obtain the crude peptide. 4) Separation of crude peptide by HPLC (A: 0.075% TFA in H2O, B: ACN) After purification, the title compound (3.10 g, purity 90.80%, yield 23.44%) was obtained. .
[0221] Purification conditions: Dissolution conditions: Dissolve in ACN / H2O Equipment: Hanbon DAC-100 Mobile phase: A: H2O (0.1% TFA in H2O), B: 0.1% TFA in ACN Gradient: 18-48% 42 minutes Holding time: 30 minutes Column: Luna 250*100mm, C18, 10μm, 100Å Flow rate: 250mL / min Wavelength: 220 / 254nm Oven temperature: Room temperature
[0222] Process 7.2
[0223] [ka]
[0224] (S)-32-(3-(((S)-2-(4-((S)-2-((S)-2-Acetami (3-methylbutanamide)propanamide)phenyl)-2-((((1S,9S) -9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2 ,3,9,10,13,15-Hexahydro-1H,12H-benzo[de]pyrano[3 ',4':6,7]Indrizino[1,2-b]Quinoline-1-yl)Carbamoyl)O Xy(ethyl)amino)-3-oxopropyl)-41-amino-3,6,9,12,1 5,18,21,24,27,30-decamethyl-4,7,10,13,16,19,2 2,25,28,31,34-Undecaoxo-36,39-Dioxa-3,6,9,1 2,15,18,21,24,27,30,33-Undekaazahentetracontanoic acid (S)-1-(4-((S)-2-((S)-2-acetamide-3-methylbutaneamide (D)propanamide)phenyl)-2-aminoethyl((1S,9S)-9-ethyl-5 -Fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10, 13,15-Hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7 Indrizino[1,2-b]quinoline-1-yl)carbamate (100.0g, 1 serving) (Amount) and DMF (400g) -1-yl)oxy)-3-oxopropyl)-1-(9H-fluoren-9yl)- 16,19,22,25,28,31,34,37,40,43-decamethyl-3,12 ,15,18,21,24,27,30,33,36,39,42-Dodecaoxo-2, 7,10-trioxa-4,13,16,19,22,25,28,31,34,37, 40,43-Dodecazapentatetracontan-45-acid (121.68g) and DMF It was added to (540g) of the mixture, cooled to -5~5°C under N2, and stirred for 5~15 minutes. Add TEA (49g, 4.0 equivalents) over 15 minutes, then incubate under N2 at -5~5°C for 1~2 hours. Stirring was performed. (S)-1-(4-((S)-2-((S)-2-acetamide-3-methyl Butanamide)propanamide)phenyl)-2-aminoethyl((1S,9S)-9- Ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3, 9,10,13,15-Hexahydro-1H,12H-benzo[de]pyrano[3',4 ':6,7]Indrizino[1,2-b]Quinoline-1-yl)Carbamate (1.0g Add 0.01 equivalents of DEA and stir for 1-2 hours. Add DEA (35.4g) for 0.5 hours. The solution was added dropwise. The mixture was stirred for 12-22 hours under N2 at -5-5°C. The reaction solution was 0.5 The solution was slowly added dropwise to MTBE (14800g), transferred, cooled to 0-10°C, and then stored under N2 conditions. The mixture was stirred for 0.5 to 1 hour. The reaction mixture was filtered and washed with MTBE (1200 g). The percake was dried at 5-15°C for 5-12 hours under a flow of N2. Title compound (105.2 g, 48%) was obtained as a solid.
[0225] Process 7.3
[0226] [ka]
[0227] (S)-32-(3-(((S)-2-(4-((S)-2-((S)-2-Acetami (3-methylbutanamide)propanamide)phenyl)-2-((((1S,9S) -9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2 ,3,9,10,13,15-Hexahydro-1H,12H-benzo[de]pyrano[3 ',4':6,7]Indrizino[1,2-b]Quinoline-1-yl)Carbamoyl)O Xy(ethyl)amino)-3-oxopropyl)-45-(2,5-dioxo-2,5- Dihydro-1H-pyrrole-1-yl)-3,6,9,12,15,18,21,24, 27,30-decamethyl-4,7,10,13,16,19,22,25,28,31, 34,43-Dodecaoxo-36,39-Dioxa-3,6,9,12,15,18,2 1,24,27,30,33,42-Dodecazapentatetracontanoic acid 3-Maleimidopropionate N-hydroxysuccinimide ester (16.8g, 6 3.1 mmol) and DMF (100 g) 4-((S)-2-((S)-2-acetamide-3-methylbutanamide)propaneamide (d)phenyl)-2-((((1S,9S)-9-ethyl-5-fluoro-9-hydrox C-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro -1H,12H-benzo[de]pirano[3',4':6,7]indridino[1,2- b)Quinoline-1-yl)carbamoyl)oxy)ethyl)amino)-3-oxopropyl) Ru)-41-amino-3,6,9,12,15,18,21,24,27,30-Dekame Chill-4,7,10,13,16,19,22,25,28,31,34-Undekaoki So-36,39-dioxa-3,6,9,12,15,18,21,24,27,30, 33-Undekaazahentetracontanoic acid (100.0 g, 55.2 mmol) and DM Adding F (900g) to the solution, it was cooled to -15 to -5°C. Under N2, at -15 to -5°C for 5 minutes. Stirred for approximately 15 minutes. Add TEA (5.59g) dropwise and incubate under N2 at -15 to -5°C for 1 to 4 minutes. Stirred for 0 minutes. Add TEA (0.559g) dropwise, and store under N2 at -15 to -5°C. The mixture was stirred for 0.5 to 2 hours. MTBE (7400g) was added, and the temperature was adjusted to -5 to 5°C. The reaction mixture was filtered and washed with MTBE (600g). The filtered cake was left at 5-15°C for 5 minutes. The compound was dried under a stream of N2 for approximately 12 hours. The title compound (73.6 g, 68%) was obtained as a solid. Ta.
[0228] Part I. Preparation of ADCs with Maleimide Linker-Payload To prepare an antibody-drug conjugate containing eight drugs per antibody (DAR8) Next, IgG1 antibody is added using 6-8 molar equivalents of a reducing reagent such as DTT or TCEP. Completely reduce the antibody at 7°C for 2 hours. Then, add 50 mM EDTA to the reduced antibody. Buffer exchange was performed using a PD-10 desalting column containing mM HEPES (pH 7.0). Adjust the eluate to a protein concentration of 5-10 mg / mL with HEPES buffer. Excess protein Add the carburetor payload (e.g., 10 molar equivalents) over 1 hour, and add a substantially excess amount of L - The conjugate reaction can be stopped by adding cysteine (e.g., 6 molar equivalents). It can be stopped. The resulting ADC mixture is mixed with 25 mM histidine and 9% sucrose (pH 5 5) Purified using a PD-10 desalting column equilibrated in step 5), followed by centrifugation in a 30 kDa MWCO. Three centrifugal cycles using a separation unit are performed to remove unreacted linker-payload related species. It can be removed. Finally, the obtained ADC is sterilized by filtering through a 0.2 μM filter. It can be stored at 4°C or -80°C for future use.
[0229] Part II. Preparation of ADCs with Bromoacetyl Linker-Payload To prepare an antibody-drug conjugate containing eight drugs per antibody, IgG1 The antibody was incubated at 37°C for 2 hours using 6-8 molar equivalents of a reducing agent such as DTT or TCEP. Completely reduce the antibody. Then, the reduced antibody is treated with 50 mM HEP containing 2 mM EDTA. Buffer exchange was performed using a PD-10 desalting column containing ES (pH 7.4), and the eluate was HE Adjust the protein concentration to 5-10 mg / mL with PES buffer. Excess linker payload Add L-cysteine (for example, 12 molar equivalents) over 2-3 hours to remove substantially excess L-cysteine The conjugate reaction can be stopped by adding (for example, 10 molar equivalents) of [a substance]. The resulting ADC mixture was leveled with 25 mM histidine and 9% sucrose (pH 5.5). The solution was purified using a weighted PD-10 desalting column, followed by centrifugation in a 30kDa MWCO centrifugation unit. Three centrifugal cycles are performed using this method to remove unreacted linker-payload related species. This can be done. Finally, the obtained ADC is sterile filtered through a 0.2 μM filter, and in the future It can be stored at 4°C or -80°C for use.
[0230] Example 3: Antibody binding affinity, cross-reactivity, and selectivity Characteristics of human and heterogeneous coupling of PTK-7 ADCs by surface plasmon resonance Using Biacore 8K+ equipment (Cytiva, Marlborough, MA) Recombinant human PTK7 (Acro Biosystems catalog number PT7-H5) Dynamics and affinity of the binding interaction of ADCs (2H3, Newark, DE) Lameta has been decided.
[0231] The surface of the anti-human Fc sensor is made of goat anti-human IgG Fc (Southern Biote Biacore, catalog number 2014-01 (Birmingham, AL) Series S C1 (Cytiva, catalog number BR-100535) sensor It was prepared by amine bonding to the surface at 25°C. For immobilization, 10 mM HEPES was used. 150 mM NaCl, 0.05% Surfactant P20, pH 7.4 A buffer solution was used. All eight channels of flow cells 1 and 2 were treated with 400 mM 1- Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 10 Using a 1:1 (v / v) mixture of 0 mM N-hydroxysuccinimide (NHS), The mixture was activated at a flow rate of 10 μL / min for 7 minutes. Then, the anti-human IgG Fc capture reagent was added. By injecting into all flow cells and channels at a flow rate of μL / min for 7 minutes, It was bound to the surface (diluted to 50 μg / mL in 10 mM acetate pH 4.5 buffer). 00 mM ethylenediamine (in 200 mM borate buffer, pH 8.5) is used in all fluoroscopy By injecting 10 μL / min into the tube and channel for 7 minutes, the remaining active groups are broken down. Locked. Next, inject 75 mM phosphate at 10 μL / min three times consecutively for 1 minute. All channels and flow cells were preconditioned accordingly.
[0232] For dynamic and affinity analysis, the running buffer and sample dilution buffer should be 10 mM. HEPES, 150mM NaCl, 0.05% Surfactant P20, pH The measured concentration was 7.4 mg / mL bovine serum albumin (BSA), and the analysis temperature was 37°C. .
[0233] In each analysis cycle, a different ADC was added to a 5 μg / mL solution at a rate of 10 μL / min for 2 minutes. By inter-channel injection, the analytes were captured on flow cell 2 in each channel. After capture, the same analytes were... Inject this into all eight channels of flow cells 1 and 2 at a rate of 30 μL / min for 2 minutes, and then dissociate. The patient was monitored for 10 minutes. After dissociation, 75 mM phosphate was injected at a rate of 10 μL / min for 1 minute, three times. By repeating the process continuously, all surfaces were regenerated. ADC capture and analyte cycle Repeat for 0, 2.47, 7.41, 22.2, 66.7, 200 and 600 nM Human PTK7 analyte binding was obtained for each ADC at different precipitate concentrations.
[0234] As shown in Table 4, the sensorgram data is obtained by subtracting the reference and the blank. After Biacore Insight Evaluation Software v3 Using the default 1:1 coupling model in .0.12.15655, the overall fit I made it happen.
[0235] The specific antibodies in this disclosure, including Ab1-4, are used in cynomolgus monkeys to obtain K in the nM range.D They are joined together.
[0236] [Table 7] Dynamic and affinity parameters of ADC / human PTK7 interaction at 37°C. a is The combined rate constant is k d is the dissociation rate constant, and K D (K) is the equilibrium dissociation constant. D =k d / k a (Calculated using)
[0237] Characteristics of cell surface binding of PTK-7 antibodies in cell lines expressing the PTK-7 receptor. The specific PTK-7 antibody described herein was applied to the cell surface of three PTK-7 expressing tumor cell lines. The combination was tested. Cell lines were selected to represent high, medium, and low receptor densities. OV 90-PTK-7 is an overexpressing, manipulated ovarian tumor cell line, NCI-H44, which exhibits high expression. Human lung cancer cells showed moderate endogenous expression, and OVCAR-3 human ovarian cancer cells showed... Low endogenous expression is observed in OV90-PTK-7, NCI-H446, and OVCAR3 cells. These have antibody binding capacities of ~500,000, ~40,000, and ~20,000, respectively. This was then determined (using the MESF Quantitative Kit, Bangs Laboratories). ). OV90 parent cells and Namalwa-luc-GFP cells were used in PTK-7 negative cell lines. This was selected. Antibody binding was quantified by flow cytometry, and the EC of the binding curve was measured. 50 Both the maximum binding MFI for each antibody and the maximum binding MFI were recorded.
[0238] Cells were dissociated at 37°C for 5 minutes using a non-enzymatic dissociation buffer. The cells were counted and the V-bottom was used. Polypropylene 96-well plates were seeded with 10 5 cells / well. The cells were centrifuged at 1800 r pm × 3 minutes, and the supernatant was discarded. Starting from 300 nM in assay buffer (1× PBS containing 5% FBS), serial dilutions of the antibody were made at a 1:4 ratio to prepare an 11-point antibody dilution series. The dilution series was added to the cells at 100 μL / well and mixed by pipetting. Several untreated control wells / cell lines were prepared with assay buffer only. The cells and antibody were incubated on an orbital shaker at 4 °C for 1 hour. After incubation, the assay plates were centrifuged and washed twice with 300 μL / well of assay buffer Then, the cell pellet was stained with a 1:500 dilution (100 μL / well) of Alexa647-conjugated mouse anti-human IgG secondary antibody in assay buffer. The assay plates were incubated in the dark at 4 °C for 1 hour with shaking. After incubation, the plates were centrifuged and the cells were washed twice with 300 μL / well of assay buffer A 1:2000 dilution of Zombie Green live / dead marker in 1× PBS was dispensed at 100 μL / well to the cells, and the plates were incubated at room temperature for 10 minutes with shaking in the dark. Then, the cell pellet was washed once with assay buffer and fixed with 4% paraformaldehyde in 200 μL / well of 1× PBS at room temperature for 15 minutes in the dark. The cells were centrifuged, washed, and then resuspended in 100 μL of assay buffer and acquired on an Attune Cytp ix Cytometer.
[0239] Cells were acquired on an Attune Cytpix Cytometer, and Attune (commercial (Standard) Using Cytometric Software (v.6.0.1) FCS file I generated the file. Then, I analyzed the FCS file with FlowJo (v10.8.1). Debris is removed from analysis by forward scattering (FSC) versus side scattering (SSC) gating. Remove and use forward scattering area (FSC-A) versus height (FSC-H) gating to separate the single cells. That was the selection. Finally, dead cells that were positive for Zombie Green staining were excluded. The MFI of Alexa647-positive live cells was quantified. The data was graphed. Analysis was performed using Pad Prism (v10.1.1). EC 50 Agonist vs. Response - Possible The maximum binding of cofetuzumab is determined via variable gradient (4-parameter) curve fitting. By setting the percentage to 100% by the mean of the maximum cofetuzumab MFI in each cell line. I calculated it.
[0240] The specific PTK7 antibody in this disclosure is, as expected, a PTK-7 negative cell line (OV). 90 did not bind to parent and namalwa-luc-GFP. The four antibodies shown in Table 5... The body bound to all three types of PTK-7 expressing tumor cells.
[0241] [Table 8] MFI = Average Fluorescence Intensity
[0242] Example 4: ADC coupling and internalization PTK-7 antibody and ADC in human PTK-7-positive cells using fluorescence imaging. Characteristics of internalization ability Single-clonal HeLa PTK-7-eGFP overexpression cells were subjected to 384 wells. Plate (PhenoPlate 384 wells, black, optically transparent flat bottom, tissue culture processing) Completed, PerkinElmer 6057308) with 5000 cells per well, complete Seed in total culture medium (DMEM, +10% FBS + Glutamax + Pen / Strep) The cells were inoculated. The next day, the cells were treated with 6 μg / mL (40 nM) ADC or antibody and 6 μg / mL ( pHrodo-labeled reagent (Zenon® pHrodo®) at a concentration of 120 nM iFL IgG Labeling Reagent, Catalog Number: Z25612, Invitrogen (Trademark) ) was treated. Before adding to the cells, the ADC or antibody was mixed with pHrodo-labeled reagent and at least It was mixed for 10 minutes. Then, Opera Phenix Plus High Contents Using a leaning system, cells were imaged every 90 minutes for up to 24 hours. The data was then processed. Then, analyze with Harmony and Microsoft Excel, and GraphPad I graphed it using Prism.
[0243] As shown in Table 6, PTK-7 antibodies and PTK-7 ADCs are used in cofetuzumabup It exhibits superior lysosomal transport (approximately twice as efficient) compared to lidotin.
[0244] [Table 9]
[0245] Example 5: ADC cytotoxicity and bystander activity Low (OVCAR-3, ABC=~20,000) and high (OV90-PTK-7, AB) Characteristics of PTK-7 ADC activity in PTK-7 expressing cell lines (C=~500,000) OVCAR3 cells were cultured in a white transparent bottom 96-well tissue culture plate (OVCAR 3: ATCC modified RPMI 1640 + 1xGlutaMax + 20% heat-inactivated bovine fetus The cells were seeded in calf serum (+10 μg / mL bovine insulin). The cells were stored at 37°C in 5% CO2. It was incubated overnight. The next day, the ADC was added to the culture medium from the final working concentration of 200 nM. The solution was added after being continuously diluted 1:4 inside the container. The plate was Breathe-Easy®. The cells were covered with a sealing membrane and incubated at 37°C with 5% CO2. After 7 days of treatment, CellT iter-Glo Luminescent Cell Viability Assa The plate was read using y. 100 μL / well CellTiter-Glo The reagents were incubated in the plate at room temperature for 10 minutes. The luminescence was measured using SpectraMax. Read with M5e. RLU (Relative Luminous Unit) was calculated using SoftMax Pro 5.4. The results were obtained. The rate of cell death was calculated relative to the untreated group (0%). The data was graphed, and Gr Analysis was performed using aphpad Prism version v10.1.1. 50 teeth, Determined by log(inhibitor) vs. response-variable gradient (4 parameters) curve fitting. Ta.
[0246] OV90-PTK-7 manipulated cell line cultured in medium (1:1 MCDB105:Medium 199+ Seeds were seeded in 15% heat-inactivated fetal bovine serum + 1×Glutamax. ADC was used as the final crop. The solution was initially administered at a concentration of 200 nM, then sequentially diluted 1:4 in culture medium and added for 5 days.
[0247] Certain PTK-7 ADCs in this disclosure have differential expression levels in PTK-7 cells. In this strain, it exhibits potent maximum cell death similar to cofetuzumab-peridotin conjugate. Shown. IC 50 The values showed similar efficacy across all ADCs in OV90-PTK-7 cells. This suggests that the potency and the efficacy of ADCs tested in OVCAR3 cells vary. No nonspecific cytotoxicity was observed in the OV90 parent (PTK-7 negative cell line).
[0248] [Table 10]
[0249] OV90-PTK-7 and NCI-H446 (PTK-7 positives with different expression levels) Namalwa-Luc-GFP cells (PTK-7 negative cell line) co-cultured with sex cell line Characteristics of the bystander effect of PTK-7 ADCs in ) In a transparent, flat-bottomed 96-well plate, OV90-PTK-7:Namalwa-L Mix uc-GFP cloned cells with culture medium (1:1 MCDB105:Medium). Combine 199 + 15% heat-inactivated fetal bovine serum + 1x Glutamax in a 2:1 ratio. A total of 3000 cells were seeded per well in 100 μL. (Namalwa-Luc-GFP cells) The PTK-7 expression test was negative. The plate was incubated overnight at 37°C in 5% CO2. The solution was incubated. The next day, the ADC was added to the culture medium at a ratio of 1:4, down from the final working concentration of 50 nM. The solution was added after continuous dilution. The plate was covered with a Breathe-Easy® encapsulation film. After 5 days of treatment, the ONE-Glo® luciferase assay system was used. The plate was read. 100 μL / well of ONE-Glo® assay reagent was used. The plates were incubated at room temperature for 10 minutes. Luminescence was observed using a SpectraMax M5e. The data was read using SoftMax Pro 5.4 to obtain the RLU (Relative Luminous Unit). The mortality rate of Namalwa-Luc-GFP was calculated against the untreated group (0%). The data was graphed using Graphpad Prism version v10.1.1. Analyzed. IC 50 log(inhibitor) vs. response (3 parameters) for ADC cytotoxicity This was determined by curve fitting.
[0250] In a transparent, flat-bottomed 96-well plate, NCI-H446:Namalwa-Luc - Mix GFP cloned cells and culture medium (RPM1 1640 + 10% heat-inactivated bovine Fetal serum + 1 × Glutamax + 1 mM sodium pyruvate) in a total ratio of 9:1 Cells were seeded at 5000 cells / well / 100 μL. The plates were incubated overnight at 37°C with 5% CO2. Incubated. The next day, ADC was added to the culture medium at a final working concentration of 300 nM. The solution was added after being continuously diluted to 4:4. The plate was sealed with Breathe-Easy®. The ONE-Glo® luciferase assay system was covered with [the specified substance]. After 7 days of treatment, the ONE-Glo® luciferase assay system was administered. I used it to read the plate.
[0251] As shown in Table 8, the specific PTK-7 ADCs of this disclosure are OV-positive cell lines. In Namalwa-Luc-GFP cells possessing 90-PTK-7, cofetuzumab It showed better bystander efficacy than peridotin, and as a positive cell line, NCI-H446 Namalwa-Luc-GFP cells exhibited a similar bystander effect. Ta.
[0252] [Table 11]
[0253] Example 6: ADCC, ADCP, and / or CDC assay In vitro antibody-dependent cell-mediated cytotoxicity (ADCC) assay of PTK-7 antibody The OV90 cell line was subjected to high levels of human PTK-7 with an antibody binding capacity of 500,000. The expression was manipulated (MESF quantification kit, Bangs Laboratories). (using s). Target cells, OV90-human PTK-7, in a clear tissue culture 96-well plate. Test medium (IMDM + 1x GlutaMax + 10% heat-inactivated fetal bovine serum + Pen -Add to Strep (100U / mL~100μg / mL) and ferment at 37°C in 5% CO2. Incubated overnight. The next day, 40 μL / well of antibody was added to the final working concentration of 200 nM. Then, the antibody was added after being serially diluted 1:3 in the test medium. The antibody was incubated at 37°C and 5% CO2 for 1 hour. Inter-incubation was performed. Then, effector cells, Jurkat-Lucia NFA T-CD16 was added at a rate of 150,000 / 80 μL / well and incubated at 37°C with 5% CO2. The solution was incubated. After 24 hours, 20 μL of supernatant and 50 μL of pre-prepared QUANT were added. I-Luc / well was mixed in a white opaque plate. Emission was measured with SpectraMax. Read with M5e. RLU (Relative Luminous Unit) was calculated using SoftMax Pro 5.4. Using GraphPad Prism version 9.5.1, the compound concentration on the X axis was obtained. The degrees were plotted on the Y-axis.
[0254] Unlike cofetuzumab antibodies that have wild-type IgG1 Fc, the PTK7 A antibody disclosed herein b1-4 were effector null antibodies and did not produce antibody-dependent cell-mediated cytotoxicity. .
[0255] In vitro antibody-dependent cell phagocytosis (ADCP) assay of PTK-7 antibody The OV90 cell line was subjected to high levels of human PTK-7 with an antibody binding capacity of 500,000. The expression was manipulated (MESF quantification kit, Bangs Laboratories). (using s). Target cells, OV90-human PTK-7, in a clear tissue culture 96-well plate. Test medium (IMDM + 1x GlutaMax + 10% heat-inactivated fetal bovine serum + Pen - Seeds are sown in Strep (100U / mL~100μg / mL) and then bred at 37°C in 5% CO2. The mixture was incubated overnight. The next day, 40 μL / well of mAb was added to the final working concentration of 200 nM. Then, add the solution after sequentially diluting it 1:3 in the test medium and incubate at 37°C and 5% CO2 for 1 hour. I baited it. Next, effector cells, Jurkat-Lucia NFAT-CD3 Add 2 at a rate of 200,000 / 80 μL / well and incubate at 37°C with 5% CO2. After 24 hours, 20 μL of supernatant and 50 μL of pre-prepared QUANTI-Luc were added. The mixture was mixed in a white opaque plate. The luminescence was read with SpectraMax M5e. I obtained the RLU (Relative Luminous Unit) using SoftMax Pro 5.4, and G Using raphPad Prism version 9.5.1, the compound concentration on the X axis is... The data was plotted on the Y-axis.
[0256] Unlike cofetuzumab antibodies that have wild-type IgG1 Fc, the PTK-7 of this disclosure Ab1-4 were effector null antibodies and did not impart antibody-dependent cell phagocytosis. Ta.
[0257] In vitro complement-dependent cell-mediated cytotoxicity (CDC) assay of PTK-7 antibody The OV90 cell line was used to generate high levels of human PTK7 with an antibody binding capacity of 500,000. The kit was manipulated to show the results (MESF quantification kit, Bangs Laboratories). (Using) OV90-human PTK7 cells were placed in a white transparent bottom 96-well tissue culture plate. Issei medium (1:1 MCDB105 / Medium199 + 1xGlutaMax + 1 In addition to 5% thermo-inactivated fetal bovine serum, the eggs were incubated overnight in a 37°C, 5% CO2 incubator. Incubated. The next day, 50 μL / well of antibody was added to the final working concentration of 200 nM. The solution is then added in assay medium after being sequentially diluted 1:3, and incubated at 37°C in 5% CO2 for 1 hour. The mixture was then baited. Next, diluted human serum complement (1:3) was added to the assay medium at a rate of 50 μL / wet. The sample was added using a syringe and incubated at 37°C in 5% CO2 for 3 hours. CellTiter-G Using the Luminescent Cell Viability Assay The plate was read. 100 μL / well of CellTiter-Glo reagent was poured in. During incubation, the samples were incubated at room temperature for 10 minutes. The luminescence was read using SpectraMax M5e. I obtained the RLU (relative luminescence unit) using SoftMax Pro 5.4. The mortality rate was calculated compared to the untreated population. The data was graphed using GraphPad Pro. The analysis was performed using ISM version 9.5.1.
[0258] As a positive control, Jeko-1 cells were incubated in assay medium (RPMI1640 + 1×Glu). Treat with anti-CD20 antibody in taMAX + 10% thermo-inactivated fetal bovine serum as described above. Ta.
[0259] Similar to cofetuzumab, PTK-7 Ab1-4 of this disclosure are PTK-7 expression OV9 The 0 cell line did not exhibit CDC activity. The anti-CD20 control antibody induced CDC activity. It was then used as a positive control in Jeko-1 cells expressing CD20.
[0260] Example 7: Efficacy of PTK-7 ADC in a tumor xenograft model Female nude mice of Envigo with thymus defects, weighing 18-20 grams and aged 5-7 weeks, were given the following treatment: 5 × 10^6 OVCAR3s containing 50% Matrigel in a NC equilibrium salt solution, NC I-H446 or OV90-PTK7 cells were subcutaneously transplanted into the right flank. The tumor was approximately 150- 250mm 3 When this is reached, the animals are divided into a treatment group or a control group based on tumor volume, and medication is administered. The study began (Day 0, n=5-8 per group). The test substance was formulated using 5% dextrose. Quality, single dose (2 mg / kg for OVCAR3 and NCI-H446, OV90- PTK7 was administered intravenously at a dose of 0.5 mg / kg. The tumor was examined using a digital caliper. Measurements were taken every other week.
[0261] As shown in Table 8, treatment with PTK-7 ADC using Ab1-4 is performed by Ben In OVCAR3 cell lines, which are more effective than the well-known cofetuzumab-peridotin ADC This resulted in the inhibition of tumor growth.
[0262] [Table 12] SEM = Standard Error of the Mean
[0263] Example 8: Stability and Tolerability Stability of ADCs with the PTK7 antibody of this disclosure having PSAR10-VA-exatecan This was evaluated in rat and human plasma (100 ug / mL). DA was evaluated over 7 days. The loss of R was minimized (~2).
[0264] The PTK7 antibody of this disclosure (together with PSAR10-VA-exatecan) The tolerability of ADC was tested in 2-instar male cynomolgus monkeys. On day 1, the cynomolgus monkeys were given... And on day 22, 50 mg / kg was slowly administered as a bolus IV injection. The sample was prepared before administration and in the same manner. After administration, ~0.5 (30 minutes), 1, 4, 8, 24, 48, 96, and 168, and ( (Only on day 1) Samples were collected at 240, 336, and 504 hours. Bioanalysis was performed using qualified methods. The procedure was performed by LCMS. ADA was not detected. Death, hematopoietic system (BM, thymus, There were no signs of spleen, hematology, or GI system (minimum to moderate histopathological changes in the GI ducts). T1 / 2 was approximately 8 days.
[0265] Amino acid and nucleotide sequences Sequence ID 1 (Human PTK-7) MGAARGSPARPRRLPLLSVLLLPLLGGTQTAIVFIKQPS SQDALQGRRALLRCEVEAPGPVHVYWLLDGAPVQDTERRF AQGSSLSFAAVDRLQDSGTFQCVARDDVTGEEARSANASF NIKWIEAGPVVLKHPASEAEIQPQTQVTLRCHIDGHPRPT YQWFRDGTPLSDGQSNHTVSSKERNLTLRPAGPEHSGLYS CCAHSAFGQACSSQNFTLSIADESFARVVLAPQDVVVARY EEAMFHCQFSAQPPPSLQWLFEDETPITNRSRPPHLRRAT VFANGSLLLTQVRPRNAGIYRCIGQGQRGPPIILEATLHL AEIEDMPLFEPRVFTAGSEERVTCLPPKGLPEPSVWWEHA GVRLPTHGRVYQKGHELVLANIAESDAGVYTCHAANLAGQ RRQDVNITVATVPSWLKKPQDSQLEEGKPGYLDCLTQATP KPTVVWYRNQMLISEDSRFEVFKNGTLRINSVEVYDGTWY RCMSSTPAGSIEAQARVQVLEKLKFTPPPQPQQCMEFDKE ATVPCSATGREKPTIKWERADGSSLPEWVTDNAGTLHFAR VTRDDAGNYTCIASNGPQGQIRAHVQLTVAVFITFKVEPE RTTVYQGHTALLQCEAQGDPKPLIQWKGKDRILDPTKLGP RMHIFQNGSLVIHDVAPEDSGRYTCIAGNSCNIKHTEAPL YVVDKPVPEESEGPGSPPPYKMIQTIGLSVGAAVAYIIAV LGLMFYCKKRCKAKRLQKQPEGEEPEMECLNGGPLQNGQP SAEIQEEVALTSLGSGPAATNKRHSTSDKMHFPRSSLQPI TTLGKSEFGEVFLAKAQGLEEGVAETLVLVKSLQSKDEQQ QLDFRRELEMFGKLNHANVVRLLGLCREAEPHYMVLEYVD LGDLKQFLRISKSKDEKLKSQPLSTKQKVALCTQVALGME HLSNNRFVHKDLAARNCLVSAQRQVKVSALGLSKDVYNSE YYHFRQAWVPLRWMSPEAILEGDFSTKSDVWAFGVLMWEV FTHGEMPHGGQADDEVLADLQAGKARLPQPEGCPSKLYRL MQRCWALSPKDRPSFSEIASALGDSTVDSKP
[0266] Sequence ID 2 (HC of Ab1) EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYIMNWVRQ APGKGLEWVSSISSSSTFIYYADSVKGRFTISRDNAKNSL YLQMNSLRAEDTAVYYCAKGFDYWGQGTLVTVSSASTKGP SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVN HKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVFLF PPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFNWYVDGVE VHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKV SNKALPAPIEKTISKAKGQPREPQVYTLPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGS FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL SPGK
[0267] Sequence ID 3 (LC of Ab1) DIQLTQSPSFLSASVGDRVTITCRASQDISSYLVWYQQK PGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQ PEDFATYYCQQLNTYPRTFGQGTKVEIKRTVAAPSVFIFP PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTHQ GLSSPVTKSFNRGEC
[0268] Sequence ID 4 (HCDR1 of Ab1) AASGFTFSSYIMN
[0269] Sequence ID 5 (HCDR2 of Ab1) SISSSSTFIY
[0270] Sequence ID 6 (HCDR3 of Ab1) AKGFDY
[0271] Sequence ID 7 (LCDR1 of Ab1) RASQDISSYLV
[0272] Sequence ID 8 (LCDR2 of Ab1) YAASTLQS
[0273] Sequence ID 9 (LCDR3 of Ab1) QQLNTYPRT
[0274] Sequence ID 10 (VH of Ab1) EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYIMNWVRQ APGKGLEWVSSISSSSTFIYYADSVKGRFTISRDNAKNSL YLQMNSLRAEDTAVYYCAKGFDYWGQGTLVTVSS
[0275] Sequence ID 11 (VL of Ab1) DIQLTQSPSFLSASVGDRVTITCRASQDISSYLVWYQQK PGKAPKLLIYAASTLQSGVPSRFSGSGSGTEFTLTISSLQ PEDFATYYCQQLNTYPRTFGQGTKVEIK
[0276] Sequence ID 12 (HC of Ab2) QVQLQESGPGLVKPSETLSLTCTVSGGSISTYYWSWIRQ PAGKGLEWIGRIYTSGLTNYNPSLKSRVTMSVDTSKNQFS LKLSSVTAADTAVYYCARDPHYYDGSGFDYWGQGTLVTVS SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQ TYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAG GPSVFLFPPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPSRE EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY TQKSLSLSPGK
[0277] Sequence ID 13 (LC of Ab2) EIVLTQSPGTLSLSPGERATLSCRASQSVSDNYLAWYQQ KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL EPEDFAVYYCQQYGSSPFTFGGPGTKVDIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC
[0278] Sequence ID 14 (HCDR1 of Ab2) TVSGGSISTYYWS
[0279] Sequence ID 15 (Ab2's HCDR2) RIYTSGLTN
[0280] Sequence ID 16 (HCDR3 of Ab2) ARDPHYYDGSGFDY
[0281] Sequence ID 17 (LCDR1 of Ab2) RASQSVSDNYLA
[0282] Sequence ID 18 (LCDR2 of Ab2 and Ab4) YGASSRAT
[0283] Sequence ID 19 (LCDR3 of Ab2) QQYGSSPFT
[0284] Sequence ID 20 (VH of Ab2) QVQLQESGPGLVKPSETLSLTCTVSGGSISTYYWSWIRQ PAGKGLEWIGRIYTSGLTNYNPSLKSRVTMSVDTSKNQFS LKLSSVTAADTAVYYCARDPHYYDGSGFDYWGQGTLVTVS S
[0285] Sequence ID 21 (VL of Ab2) EIVLTQSPGTLSLSPGERATLSCRASQSVSDNYLAWYQQ KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL EPEDFAVYYCQQYGSSPFTFGPGTKVDIK
[0286] Sequence ID 22 (HC of Ab3) QVQLQESGPGLVKPSETLSLTCTVSGGSISTYYWNWIRQ PAGKGLEWIGRIYSSGSTNYNPSLKSRVTMSVDTSKNQFS LKLSSVTAADTAVYYCARDPLYSGSLFDIWGQGTMVTVSS ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGG PSVFLFPPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK
[0287] Sequence ID 23 (LC of Ab3) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ KPGQAPRLLIYGASIRATGIPDRFSGSGSGTDFTLTISRL EPEDFAVYYCQQYGSSPYTFGQGTKLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC
[0288] Sequence ID 24 (HCDR1 of Ab3) TVSGGSISTYYWN
[0289] Sequence ID 25 (Ab3's HCDR2) RIYSSGSTN
[0290] Sequence ID 26 (Ab3's HCDR3) ARDPLYSGSLFDI
[0291] Sequence ID 27 (LCDR1 of Ab3) RASQSVSSSYLA
[0292] Sequence ID 28 (LCDR2 of Ab3) YGASIRAT
[0293] Sequence ID 29 (LCDR3 of Ab3) QQYGSSPYT
[0294] Sequence ID 30 (VH of Ab3) QVQLQESGPGLVKPSETLSLTCTVSGGSISTYYWNWIRQ PAGKGLEWIGRIYSSGSTNYNPSLKSRVTMSVDTSKNQFS LKLSSVTAADTAVYYCARDPLYSGSLFDIWGQGTMVTVSS
[0295] Sequence ID 31 (VL of Ab3) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQ KPGQAPRLLIYGASIRATGIPDRFSGSGSGTDFTLTISRL EPEDFAVYYCQQYGSSPYTFGQGTKLEIK
[0296] Sequence ID 32 (HC of Ab4) EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQ APGKGLEWVSSIDSSSSFIYYADSVKGRFTISRDNAKNSL YLQMNSLRAEDTAVYYCARGTGLFDFWGQGTLVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS GALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYIC NVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSV FLFPPKPKDTLMISRTPEVTCVVVSVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPSREEMTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK
[0297] Sequence ID 33 (LC of Ab4) EIVLTQSPGTLSLSPGERATLSCRASQSFSSSYLAWYQQ KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL EPEDFAVYYCQQYGRTPWTFGQGTKVEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN SQESVTEQDSKDSTYSLSSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC
[0298] Sequence ID 34 (HCDR1 of Ab4) AASGFTFSSYSMN
[0299] Sequence ID 35 (HCDR2 of Ab4) SIDSSSSFIY
[0300] Sequence ID 36 (HCDR3 of Ab4) ARGTGLFDF
[0301] Sequence ID 37 (LCDR1 of Ab4) RASQSFSSSYLA
[0302] Sequence ID 38 (LCDR3 of Ab4) QQYGRTPWT
[0303] Sequence ID 39 (VH of Ab4) EVQLVESGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQ APGKGLEWVSSIDSSSSFIYYADSVKGRFTISRDNAKNSL YLQMNSLRAEDTAVYYCARGTGLFDFWGQGTLVTVSS
[0304] Sequence ID 40 (VL of Ab4) EIVLTQSPGTLSLSPGERATLSCRASQSFSSSYLAWYQQ KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRL EPEDFAVYYCQQYGRTPWTFGQGTKVEIK
[0305] Sequence ID 41 (DNA of HC against Ab1) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAG CCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAT TCACCTTCAGTAGCTATATCATGAACTGGGTCCGCCAGGC TCCAGGGAAGGGACTGGAGTGGGTCTCTTCCATTAGTAGT AGTAGTACTTTCATATACTACGCAGACTCAGTGAAGGGCC GATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTA TCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCTGTG TATTACTGTGCGAAAGGTTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCAgcctccaccaagggcccatc ggtcttccccctggcaccctcctccaagagcacctctggg ggcacagcggccctgggctgcctggtcaaggactacttcc ccgaaccggtgacggtgtcgtggaactcaggcGCGctgac cagcggcgtgcacaccttcccggctgtcctacagtcctca ggactctactccctcagcagcgtggtgaccgtgccctcca gcagcttgggcacccagacctacatctgcaacgtgaatca caagcccagcaacaccaaggtggacaagagagttgagccc aaatcttgtgacaaaactcacacatgcccaccgtgcccag cacctgaagccgccgggggaccgtcagtcttcctcttccc cccaaaacccaaggacaccctcatgatctcccggacccct gaggtcacatgcgtggtggtgtccgtgagccacgaagacc ctgaggtcaagttcaactggtatgtggacggcgtggaggt gcataatgccaagacaaagccgcgggaggagcagtacaac agcacgtaccgtgtggtcagcgtcctcaccgtcctgcacc aagactggctgaatggcaaggagtacaagtgcaaggtctc caacaaagccctcccagcccccatcgagaaaaccatctcc aaagccaaagggcagccccgagaaccacaggtgtacaccc tgcccccatcccgggaggagatgaccaagaaccaagtcag cctgacctgcctggtcaaaggcttctatcccagcgacatc gccgtggagtgggagagcaatgggcagccggagaacaact acaagaccacgcctcccgtgctggactccgacggctcctt cttcctctattccaagctcaccgtggacaagagcaggtgg cagcaggggaacgtcttctcatgctccgtgatgcatgagg ctctgcacaaccactacacgcagaagagcctctccctgtc tccgggcaaatga
[0306] SEQ ID NO: 42 (DNA of LC against Ab1) GACATCCAGTTGACCCAGTCTCCATCCTTCCTGTCTGCA TCTGTAGGAGACAGAGTCACCATCACTTGCCGGGCCAGTC AGGACATTAGCAGTTATTTAGTCTGGTATCAGCAAAAACC AGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACT TTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT CTGGGACAGAATTCACTCTCACAATCAGCAGCCTGCAGCC TGAAGATTTTGCAACTTATTACTGTCAACAACTTAATACT TACCCTCGGACGTTCGGCCAAGGGACCAAGGTGGAAATCA AAagaactgtggcggcgccatctgtcttcatcttcccgcc atctgatgagcagttgaaatccggaactgcctctgttgtg tgcctgctgaataacttctatcccagagaggccaaagtac agtggaaggtggataacgccctccaatcgggtaactccca ggagagtgtcacagagcaggacagcaaggacagcacctac agcctcagcagcaccctgacgctgagcaaagcagactacg agaaacacaaagtctacgcctgcgaagtcacccatcaggg cctgagctcgcccgtcacaaagagcttcaacaggggagag tgctaa
[0307] Sequence number 43 (DNA of HC against Ab2) CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAG CCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTG GCTCCATCAGTACTTACTACTGGAGCTGGATCCGGCAGCC CGCCGGGAAGGGACTGGAGTGGATTGGACGTATCTATACC AGTGGTCTCACCAACTACAACCCCTCCCTCAAGAGTCGAG TCACCATGTCTGTAGACACGTCCAAGAACCAGTTCTCCCT GAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTATAT TACTGTGCGAGAGACCCCCATTACTATGATGGTAGTGGTT TTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTC Agcctccaccaagggcccatcggtcttccccctggcaccc tcctccaagagcacctctgggggcacagcggccctgggct gcctggtcaaggactacttccccgaaccggtgacggtgtc gtggaactcaggcGCGctgaccagcggcgtgcacaccttc ccggctgtcctacagtcctcaggactctactccctcagca gcgtggtgaccgtgccctccagcagcttgggcacccagac ctacatctgcaacgtgaatcacaagcccagcaacaccaag gtggacaagagagttgagcccaaatcttgtgacaaaactc acacatgcccaccgtgcccagcacctgaagccgccggggg accgtcagtcttcctcttccccccaaaacccaaggacacc ctcatgatctcccggacccctgaggtcacatgcgtggtgg tgtccgtgagccacgaagaccctgaggtcaagttcaactg gtatgtggacggcgtggaggtgcataatgccaagacaaag ccgcgggaggagcagtacaacagcacgtaccgtgtggtca gcgtcctcaccgtcctgcaccaagactggctgaatggcaa ggagtacaagtgcaaggtctccaacaaagccctcccagcc cccatcgagaaaaccatctccaaagccaaagggcagcccc gagaaccacaggtgtacaccctgcccccatcccgggagga gatgaccaagaaccaagtcagcctgacctgcctggtcaaa ggcttctatcccagcgacatcgccgtggagtgggagagca atgggcagccggagaacaactacaagaccacgcctcccgt gctggactccgacggctccttcttcctctattccaagctc accgtggacaagagcaggtggcagcaggggaacgtcttct catgctccgtgatgcatgaggctctgcacaaccactacac gcagaagagcctctccctgtctccgggcaaatga
[0308] Sequence number 44 (DNA of LC for Ab2) GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTG TCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTC AGAGTGTTAGCGACAACTACTTAGCCTGGTACCAGCAGAA ACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCC AGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGA GCCTGAAGATTTTGCAGTGTACTACTGTCAGCAGTATGGT AGTTCACCATTCACTTTCGGCCCTGGGACCAAGGTGGATA TCAAAagaactgtggcggcgccatctgtcttcatcttccc gccatctgatgagcagttgaaatccggaactgcctctgtt gtgtgcctgctgaataacttctatcccagagaggccaaag tacagtggaaggtggataacgccctccaatcgggtaactc ccaggagagtgtcacagagcaggacagcaaggacagcacc tacagcctcagcagcaccctgacgctgagcaaagcagact acgagaaacacaaagtctacgcctgcgaagtcacccatca [[ID=,37]]gggcctgagctcgcccgtcacaaagagcttcaacagggga gagtgctaa
[0309] SEQ ID NO: 45 (DNA of HC against Ab3) CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAG CCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCTGGTG GCTCCATCAGTACTTACTACTGGAACTGGATCCGGCAGCC CGCCGGGAAGGGACTGGAGTGGATTGGGCGTATCTATAGT AGTGGGAGCACCAACTACAACCCCTCCCTCAAGAGTCGAG TCACCATGTCAGTAGACACGTCCAAGAACCAGTTCTCCCT GAAGCTGAGCTCTGTGACCGCCGCGGACACGGCCGTGTAT TACTGTGCGAGAGATCCCTTGTATAGTGGGAGCCTTTTTG ATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCAgc ctccaccaagggcccatcggtcttccccctggcaccctcc tccaagagcacctctgggggcacagcggccctgggctgcc tggtcaaggactacttccccgaaccggtgacggtgtcgtg gaactcaggcGCGctgaccagcggcgtgcacaccttcccg gctgtcctacagtcctcaggactctactccctcagcagcg tggtgaccgtgccctccagcagcttgggcacccagaccta catctgcaacgtgaatcacaagcccagcaacaccaaggtg gacaagagagttgagcccaaatcttgtgacaaaactcaca catgcccaccgtgcccagcacctgaagccgccgggggacc gtcagtcttcctcttccccccaaaacccaaggacaccctc atgatctcccggacccctgaggtcacatgcgtggtggtgt ccgtgagccacgaagaccctgaggtcaagttcaactggta tgtggacggcgtggaggtgcataatgccaagacaaagccg cgggaggagcagtacaacagcacgtaccgtgtggtcagcg tcctcaccgtcctgcaccaagactggctgaatggcaagga gtacaagtgcaaggtctccaacaaagccctcccagccccc atcgagaaaaccatctccaaagccaaagggcagccccgag aaccacaggtgtacaccctgcccccatcccgggaggagat gaccaagaaccaagtcagcctgacctgcctggtcaaaggc ttctatcccagcgacatcgccgtggagtgggagagcaatg ggcagccggagaacaactacaagaccacgcctcccgtgct ggactccgacggctccttcttcctctattccaagctcacc gtggacaagagcaggtggcagcaggggaacgtcttctcat gctccgtgatgcatgaggctctgcacaaccactacacgca gaagagcctctccctgtctccgggcaaatga <当该配列は、配列番号46 (Ab3に対するLCのDNA) として配列番号1に示される。当该配列は、配列番号1に示される配列番号46 (Ab3に対するLCのDNA) である。
[0310] SEQ ID NO: 46 (DNA of LC for Ab3) GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTG TCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTC AGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAACAGAA ACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCC ATCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGA GCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGT AGCTCACCGTACACTTTTGGCCAGGGGACCAAGCTGGAGA TCAAAagaactgtggcggcgccatctgtcttcatcttccc gccatctgatgagcagttgaaatccggaactgcctctgtt gtgtgcctgctgaataacttctatcccagagaggccaaag tacagtggaaggtggataacgccctccaatcgggtaactc ccaggagagtgtcacagagcaggacagcaaggacagcacc tacagcctcagcagcaccctgacgctgagcaaagcagact acgagaaacacaaagtctacgcctgcgaagtcacccatca gggcctgagctcgcccgtcacaaagagcttcaacagggga gagtgctaa
[0311] SEQ ID NO: 47 (DNA of HC against Ab4) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAG CCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGAT TCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGC TCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATTGATAGT AGTAGTAGTTTCATATACTACGCAGACTCAGTGAAGGGCC GATTCACCATCTCCAGGGACAACGCCAAGAACTCACTGTA TCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTG TATTATTGTGCGAGAGGAACTGGGCTCTTTGACTTCTGGG GCCAGGGAACCCTGGTCACCGTCTCCTCAgcctccaccaa gggcccatcggtcttccccctggcaccctcctccaagagc acctctgggggcacagcggccctgggctgcctggtcaagg actacttccccgaaccggtgacggtgtcgtggaactcagg cGCGctgaccagcggcgtgcacaccttcccggctgtccta cagtcctcaggactctactccctcagcagcgtggtgaccg tgccctccagcagcttgggcacccagacctacatctgcaa cgtgaatcacaagcccagcaacaccaaggtggacaagaga gttgagcccaaatcttgtgacaaaactcacacatgcccac cgtgcccagcacctgaagccgccgggggaccgtcagtctt cctcttccccccaaaacccaaggacaccctcatgatctcc cggacccctgaggtcacatgcgtggtggtgtccgtgagcc acgaagaccctgaggtcaagttcaactggtatgtggacgg cgtggaggtgcataatgccaagacaaagccgcgggaggag cagtacaacagcacgtaccgtgtggtcagcgtcctcaccg tcctgcaccaagactggctgaatggcaaggagtacaagtg caaggtctccaacaaagccctcccagcccccatcgagaaa accatctccaaagccaaagggcagccccgagaaccacagg tgtacaccctgcccccatcccgggaggagatgaccaagaa ccaagtcagcctgacctgcctggtcaaaggcttctatccc agcgacatcgccgtggagtgggagagcaatgggcagccgg agaacaactacaagaccacgcctcccgtgctggactccga cggctccttcttcctctattccaagctcaccgtggacaag agcaggtggcagcaggggaacgtcttctcatgctccgtga tgcatgaggctctgcacaaccactacacgcagaagagcct ctccctgtctccgggcaaatga
[0312] SEQ ID NO: 48 (DNA of LC for Ab4) GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTG TCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTC AGAGTTTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAA ACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATCC AGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTG GGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGA GCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGT AGGACACCGTGGACGTTCGGCCAAGGGACCAAGGTGGAAA TCAAAagaactgtggcggcgccatctgtcttcatcttccc gccatctgatgagcagttgaaatccggaactgcctctgtt gtgtgcctgctgaataacttctatcccagagaggccaaag tacagtggaaggtggataacgccctccaatcgggtaactc ccaggagtgtcacagagcaggacagcaaggacagcacc tacagcctcagcagcaccctgacgctgagcaaagcagact acgagaaacacaaagtctacgcctgcgaagtcacccatca gggcctgagctcgcccgtcacaaagagcttcaacagggga gagtgctaa
[0313] Sequence ID 49 -Ala-Leu-Ala-Leu- (can also be written as ALAL in single letter notation) (known)
[0314] Sequence ID 50 -Leu-Ala-Leu-Ala- (can also be written as LALA in single character notation) (known)
[0315] Sequence ID 51 -Gly-Phe-Leu-Gly- (also written as GFLG in single letter notation) (known)
[0316] Sequence ID 52 -Gly-Leu-Phe-Gly- (also written as GLFG in single letter notation) (known)
[0317] Sequence ID 53 -Ala-Ala-Ala-Ala- (can also be written as AAAA in single letter notation) (known)
[0318] Sequence ID 54 -Gly-Ala-Gly-Gly-(can also be written as GAGG in single letter notation) (known)
[0319] Sequence ID 55 -Gly-Gly-Ala-Gly- (can also be written as GGAG in single letter notation) (known)
[0320] Sequence ID 56 -Gly-Val-Gly-Gly-(also usable as a single letter GVGG) (known)
[0321] Sequence ID 57 -Gly-Gly-Val-Gly-(can also be written as GGVG in single letter notation) (known)
[0322] Sequence ID 58 -Gly-Phe-Gly-Gly-(also written as GFGG in single letter notation) (known)
[0323] Sequence ID 59 -Gly-Gly-Phe-Gly- (also written as GGFG in single letter notation) (known)
Claims
1. An antibody-drug conjugate (ADC) comprising an antibody conjugated to a cytotoxic agent, wherein the antibody is bound to human PTK-7 and comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity-determining regions (HCDR) HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity-determining regions (LCDR) LCDR1, LCDR2, and LCDR3. d) ADC, wherein HCDR1 includes sequence number 34, HCDR2 includes sequence number 35, HCDR3 includes sequence number 36, LCDR1 includes sequence number 37, LCDR2 includes sequence number 18, and LCDR3 includes sequence number 38.
2. d) The ADC according to claim 1, wherein VH includes sequence number 39 and VL includes sequence number 40.
3. The antibody comprises a heavy chain (HC) and a light chain (LC), d) The ADC according to claim 1, wherein the HC comprises amino acids 2 to 444 of SEQ ID NO: 32, and the LC comprises amino acids 2 to 215 of SEQ ID NO:
33.
4. d) The ADC according to claim 3, wherein HC is sequence number 32 and LC is sequence number 33.
5. The ADC according to claim 1, wherein the cytotoxic agent is selected from the group consisting of microtubule inhibitors, topoisomerase I inhibitors, DNA damaging agents, DNA alkylating agents, and DNA subgroove binders.
6. The ADC according to claim 5, wherein the cytotoxic agent is a topoisomerase I inhibitor.
7. The ADC according to claim 6, wherein the topoisomerase I inhibitor is a camptothecin analog.
8. The aforementioned camptothecin analog is given by formula: 【Chemistry 1】 The ADC according to claim 7, comprising the compound.
9. The aforementioned ADC is given by: 【Chemistry 2】 The ADC according to claim 8, comprising the compound.
10. The ADC according to claim 9, further comprising a linker that connects the antibody to the cytotoxic agent.
11. The ADC according to claim 10, wherein the linker includes a peptide unit or a sugar-cleaving unit.
12. The ADC according to claim 11, wherein the peptide unit comprises Val-Ala, Val-Cit, Phe-Lys, or Ala-Ala-Asn.
13. The aforementioned ADC is given by: 【Transformation 3】 The ADC according to claim 12, comprising the compound.
14. The ADC according to claim 10, wherein the linker further comprises a hydrophobic masking group.
15. The ADC according to claim 14, wherein the hydrophobic masking group is selected from polysarcosine or polyethylene glycol.
16. The ADC according to claim 15, wherein the hydrophobic masking group is in a branched arrangement on the linker.
17. The aforementioned hydrophobic masking group is, formula: 【Chemistry 4】 It is a polysarcosine, In the formula, k is an integer from 6 to 12, and X 1 is H, OH, or NH 2 The ADC according to claim 16.
18. The ADC according to claim 14, wherein the linker further includes a connection unit.
19. The aforementioned connection unit is given by: 【Transformation 5】 It is one of them, The ADC according to claim 18, wherein z is 1 to 5 in the formula.
20. The aforementioned ADC is given by: 【Transformation 6】 It is one of the compounds, During the ceremony, Ab is the antibody, d) The HC contains amino acids 2 to 444 of SEQ ID NO: 32, and the LC contains amino acids 2 to 215 of SEQ ID NO: 33, and The ADC according to claim 3, wherein n is approximately 1 to 16.
21. The aforementioned ADC is given by: 【Transformation 7】 The ADC according to claim 20, which is a compound of the above.
22. The aforementioned ADC is given by: 【Transformation 8】 The ADC according to claim 20, which is a compound of the above.
23. The ADC according to claim 20, wherein the connection to the antibody occurs via one or more cysteine thiol groups of the antibody.
24. The ADC according to claim 23, wherein each of the one or more cysteines is a native cysteine in the hinge region of the antibody.
25. The ADC according to claim 24, wherein Ab comprises LC containing amino acids 2 to 444 of SEQ ID NO: 32 and amino acids 2 to 215 of SEQ ID NO: 33, and n is approximately 8.
26. An antibody that binds to human PTK-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), the VH comprising heavy chain complementarity determining regions (HCDR) HCDR1, HCDR2, and HCDR3, and the VL comprising light chain complementarity determining regions (LCDR) LCDR1, LCDR2, and LCDR3. d) An antibody in which HCDR1 includes SEQ ID NO: 34, HCDR2 includes SEQ ID NO: 35, HCDR3 includes SEQ ID NO: 36, LCDR1 includes SEQ ID NO: 37, LCDR2 includes SEQ ID NO: 18, and LCDR3 includes SEQ ID NO:
38.
27. d) The antibody according to claim 26, wherein VH includes SEQ ID NO: 39 and VL includes SEQ ID NO:
40.
28. The antibody comprises a heavy chain (HC) and a light chain (LC), d) The antibody according to claim 26, wherein the HC comprises amino acids 2 to 444 of SEQ ID NO: 32, and the LC comprises amino acids 2 to 215 of SEQ ID NO:
33.
29. d) The antibody according to claim 28, wherein the HC is sequence number 32 and the LC is sequence number 33.
30. A pharmaceutical composition comprising the ADC according to any one of claims 1 to 25 and one or more pharmaceutically acceptable carriers, diluents, or excipients.
31. A pharmaceutical composition for use in the treatment of cancer, comprising an effective amount of the ADC described in any one of claims 1 to 25.
32. The pharmaceutical composition for use according to claim 31, wherein the cancer is ovarian cancer, lung cancer, breast cancer, stomach cancer, kidney cancer, prostate cancer, liver cancer, or colorectal cancer.
33. A method for preparing an ADC, comprising conjugating an antibody according to any one of claims 26 to 29 into a linker-payload, wherein the linker-payload is of the formula: 【Chemistry 9】 A method that includes one of the following.
34. A method for producing an ADC, wherein the antibody according to any one of claims 26 to 29 is given the formula: 【Chemistry 10】 A method comprising contacting a compound with the compound.
